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ABSTRACT   
Background: 
During the past decade, there has been increased interest in vitamin D and its effect on disease 
states beyond bone and skeletal health. One of the conditions vitamin D has been associated 
with is the metabolic syndrome which consists out of four components namely obesity, 
hypertension, dyslipidaemia and glucose intolerance. The relationship between vitamin D and 
the components of the Metabolic Syndrome were investigated in this systematic review. 
Objectives:   
To assess the effects of vitamin D administration on components of the metabolic syndrome in 
various population groups. 
Search methods:   
The following electronic databases were searched: The Cochrane Central Register of controlled 
trials, Medline (accessed via Pubmed), Science Direct, ISI Web of knowledge and Scopus. The 
searches were performed in October 2010 and repeated in May 2012. Only trials of which full 
text articles were available were included. 
Selection criteria:   
Trials were included if they have a randomised controlled trial design; adult participants of any 
ethnicity with a insufficient or deficient vitamin D status and who were diagnosed with at least 
one of the components of the metabolic syndrome;  and where the effect of vitamin D at any 
dose, duration and route of administration, administered as monotherapy or in combination 
therapy, was compared to placebo or no intervention. 
 
Stellenbosch University  http://scholar.sun.ac.za
iv 
 
Data collection and analysis:   
Two authors independently selected studies for inclusion, extracted data and assessed the risk 
of bias using the Cochrane Collaboration risk of bias tool. Where data allowed, mean 
differences for continuous outcomes were calculated and  presented with 95% confidence 
intervals. Medians and ranges  or P-values were otherwise reported. 
Results:   
Four randomized controlled trials were included in this narrative review (N=373). A meta-
analysis could not be performed due to heterogeneity in study design and outcomes measured.  
The first trial (N=81) examined the effect of 4 000IU vitamin D3 supplementation versus 
placebo daily on insulin resistance in vitamin D deficient woman for six months. The authors 
found that by improving vitamin D status in insulin resistant women, both insulin resistance 
(p=0.02) and insulin sensitivity (p=0.003) improved, but there was no change in insulin 
secretion.  
The second trial (N=28) looked at the effect of high doses of vitamin D supplementation (300 
000IU vitamin D3 intramuscularly) on glucose tolerance in type 2 diabetics. There were no 
difference between the vitamin D3 and distilled water groups, outcomes were unchanged by 
vitamin D supplementation in this study.  
The third trial (N=200) compared the effects of vitamin D supplementation (332IU 
cholecalciferol daily) with placebo for one year on weight loss and cardiovascular disease risk 
markers in overweight adults. Weight loss between the two groups did not differ. Triglycerides  
significantly improved (p<0.001) in the vitamin D treated group, as well as tumor necrosis factor 
(p=0.049) LDL-Cholesterol was however increased (p<0.00l) in the vitamin D treated group. 
The fourth study (N=61) looked at varying doses of vitamin D3 on markers of vascular health in 
type 2 diabetics. No difference in endothelial function, insulin resistance or HbAIc was found 
between the groups. Systolic blood pressure (p=0.03) in the vitamin D groups improved 
compared to the control group. 
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Authors' conclusions:   
The results of the four randomized controlled trials evaluated in this systematic review are 
variable and do not provide sufficient evidence to guide clinicians as to the effects of using 
vitamin D supplementation in patients presenting with components of the metabolic syndrome.  
 
KEYWORDS: 
Vitamin D; Vitamin D supplementation; metabolic syndrome; 
systematic review 
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PLAIN LANGUAGE SUMMARY 
The possible advantages of vitamin D supplementation on various cardiometabolic conditions 
have been examined over the past few years. Vitamin D supplementation has possibly shown 
effects on each of the individual components of the metabolic syndrome i.e.: obesity, 
hypertension, dyslipidaemia and glucose intolerance. The aim of this systematic review was to 
ascertain whether or not vitamin D supplementation has any effect on any of the components 
of the metabolic syndrome. We searched the (Cochrane Central Register of Controlled Trails 
(Central), Medline, Science direct, ISI Web of knowledge and Scopus during 2010 (repeated 
search in 2012). We found four randomized controlled trials that met our inclusion and 
exclusion criteria. Three hundred and seventy three patients were included in these four 
randomized controlled trails comparing vitamin D supplementation with placebo. Duration of 
treatment was a minimum of 4 weeks, through to a maximum of on-year. The different trials 
looked at various components of the metabolic syndrome as outcomes. The results were not 
consistent amongst the trials and the results could not be combined in a meta-analysis due to 
heterogeneity in study design and outcomes measured. The current systematic review 
highlights the shortcomings in the published data and we recommend further trials be 
undertaken before vitamin D supplementation can be recommended as beneficial for patients 
with the metabolic syndrome. 
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OPSOMMING 
Agtergrond: 
Gedurende die afgelope dekade was daar toenemende belangstelling in vitamien D en die 
uitwerking daarvan op siektetoestande bo en behalwe been- en skelet-gesondheid. Een van die 
toestande waarmee vitamien D verbind word, is die metaboliese sindroom. Vitamien D is met 
elk van die individuele komponente van die sindroom verbind m.a.w. vetsug, hipertensie, 
dislipidemie en glukose-intoleransie. Die bestaan van afdoende bewyse wat sodanige verband 
steun, is in hierdie sistematiese oorsig ondersoek. 
Doelstellings: 
Om die invloed van vitamien D-toediening op komponente van die metaboliese sindroom by 
verskillende bevolkingsgroepe te bepaal. 
Soekmetodes: 
Die volgende elektroniese databasisse is nagevors: die Cochrane sentrale register van 
gekontroleerde proewe, Medline (toegang via Pubmed verkry), Science Direct, ISI Web of 
Knowledge en Scopus. 
Die soektog is in Oktober 2010 onderneem en in Mei 2012 herhaal. Slegs proewe waarvan 
volteksartikels beskikbaar was, is ingesluit. 
 
Kriteria vir seleksie: 
Proewe was ingesluit as hulle verewekansigde gekontroleerde proewe was. Dellneemers moes 
volwassens wees van enige rassegroep. Die pasiënte moes gediagnoseer wees met ten minste 
een van die komponente van die metaboliese sindroom. Proewe is vir insluiting by hierdie 
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sistematiese oorsig oorweeg indien hulle die uitwerking van vitamien D teen enige dosis, roete 
van toediening en vir enige tydsduur, as monoterapie of in kombinasieterapie toegedien, 
teenoor plasebo of geen intervensie  vergelyk het. 
Data-insameling en -analise: 
Twee outeurs het onafhanklik van mekaar studies vir insluiting gekies, data onttrek en die risiko 
van sydigheid bepaal met behulp van die Cochrane Collaboration-instrument vir die bepaling 
van die risiko van sydigheid. Indien data toegelaat het is gemiddelde verskille vir kontinue 
uitkomste bereken en die resultate is aangebied met 95% geloofwaardigheidsintervalle. 
Mediane en reikwydtes op p-waardes is gerapporteer. 
Resultate: 
Vier verewekansigde gekontroleerde proewe is by hierdie narratiewe oorsig (N=373) ingesluit. 
ŉ Meta-analise kon nie uitgevoer word nie weens heterogeniteit in die ontwerp van die 
onderskeie studies en die gemete uitkomste.  
Die eerste proef (N=81) het die uitwerking van vitamien D-aanvulling 4 000IE D3 per dag op 
insulienweerstand by vroue met vitamien D-tekort of plasebo vir ses maande ondersoek. 
Die uitkomste van hierdie proef het aangetoon dat, met verbetering van vitamien D-status by 
insulienweerstandige vroue, sowel insulienweerstand (p=0.02) as insuliensensitiwiteit (p=0.003) 
verbeter het, maar dat daar geen verandering in insuliensekresie was nie.  
Die tweede proef (N=28) het gekyk na die uitwerking van hoë dosisse vitamien D-aanvulling 
(met ander woorde 300 000IE vitamien D3 binnespiers) op glukosetoleransie by tipe 2-diabete. 
Die uitkomste was onveranderd ná vitamien D-aanvulling in hierdie studie.  
Die derde proef (N=200) het die uitwerkings van vitamien D-aanvulling 332IE cholekalsiferol 
daagliks of plasebo vir een jaar op gewigsverlies ondersoek en die risikomerkers by 
kardiovaskulêre siekte tydens gewigsverlies is nie beduidend deur vitamien D-aanvulling geraak 
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nie. Risikomerkers by kardiovaskulêre siekte soos trigliseriede is meer beduidend (p<0.001) by 
die vitamien D-behandelde groep verlaag en tumornekrosefaktor (p=0.049) by die vitamien D-
behandelde groep is ook beduidend geraak in vergelyking met die kontrolegevalle. LDL-
cholesterol het egter (p<0.00l) by die vitamien D-behandelde groep verhoog. 
Die vierde studie (N=61) het gekyk na wisselende dosisse vitamien D3 op merkers van vaskulêre 
gesondheid by tipe 2 diabete. Vitamien D-aanvulling het nie endoteelfunksie, 
insulienweerstand of HbAIc geraak nie. Sistoliese bloeddruk (p=0.03) en B-tipe natriuretiese 
peptiedvlakke (p=0.02) is verbeter. 
Outeurs se gevolgtrekkings: 
Die resultate van die vier verewekansigde gekontroleerde proewe wat in hierdie sistematiese 
oorsig geëvalueer is, is uiteenlopend en verskaf nie voldoende bewys om klinici te lei ten 
opsigte van die effek van die gebruik van vitamien D-aanvulling by pasiënte wat met 
komponente van die metaboliese sindroom presenteer nie.  
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Opsomming in eenvoudige taal 
Vitamien D-aanvullings se uitwerking op komponente van die metaboliese 
sindroom 
Die moontlike voordele van vitamien D-aanvullings op verskillende kardiometaboliese 
toestande is oor die afgelope paar jaar ondersoek. Daar is aangetoon dat vitamien D-
aanvullings uitwerkings het op elk van die individuele komponente van die metaboliese 
sindroom naamlik vetsug, hipertensie, dislipidemie en glukose-intoleransie. Die doel van hierdie 
sistematiese oorsig was om vas te stel of vitamien D-aanvullings enige uitwerking het op enige 
van die komponente van die metaboliese sindroom of nie. Ons het gedurende 2010 soektogte 
uitgevoer op die Cochrane Sentrale register van gekontroleerde proewe (Central), Medline, 
Science Direct, ISI Web of Knowledge en Scopus (soektog is in 2012 herhaal). Ons het vier 
verewekansigde gekontroleerde proewe wat aan ons insluiting- en uitsluitingskriteria voldoen 
het, opgespoor. Driehonderd drie en sewentig pasiënte is by die vier proewe ingesluit. Al vier 
proewe het vitamien D-aanvullings met plasebo vergelyk. Die duur van behandeling het van 4 
weke tot  een jaar gestrek. Die verskillende proewe het gekyk na verskillende komponente van 
die metaboliese sindroom as uitkomste. Die resultate van die onderskeie proewe was nie 
konsekwent nie. Die huidige sistematiese oorsig belig die tekortkominge in die gepubliseerde 
data en ons beveel aan dat verdere proewe onderneem word om vas te stel of dit nuttig is om 
vitamien D aanvullings vir pasiënte met die metaboliese sindroom aan te beveel, en of dit dalk 
skadelik kan wees.  
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LIST OF DEFINITIONS 
Calcifediol: a physiologic form of vitamin D.
1
 
Calciferol: a fat soluble, crystalline, unsaturated alcohol produced by ultraviolet 
irradiation of ergosterol and used as a dietary supplement in the prophylaxis and 
treatment of rickets, osteomalacia, and other hypocalcemic disorders. It occurs 
naturally in milk and fish-liver oils. Also called ergocalciferol, oleovitamin D2, 
vitamin D2.1
  
Immunoassay: a competitive-binding assay in which the binding protein is an 
antibody.
1
 
Chemiluminescence assay: chemiluminescence is the name given to light 
emission produced during a chemical reaction.
2
 
Liquid chromatography mass-spectrometric detection: Identifying a substance by 
sorting a stream of charged particles according to their mass.1  
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CHAPTER 1:  
BACKGROUND AND MOTIVATION FOR THE STUDY 
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1.1 INTRODUCTION 
For more than twenty years we have witnessed an increased interest and research in the role of 
vitamin D. There have been numerous articles published in both the scientific journals and popular 
media concerning a wide range of possible health effects.  Of particular interest is the possible non-
skeletal effects of vitamin D such as in cancer, autoimmune diseases and the various components of 
the metabolic syndrome.    
The list of diseases for which vitamin D has been claimed to have an effect has grown so extensively 
it would appear that this vitamin is the panacea for all ills.
3
  
Over the past few decades, the incidence of the metabolic syndrome has increased and affects as 
much as 25% of the population. A possible role of vitamin D in the various components of the 
metabolic syndrome has been postulated.
4
  Metabolic syndrome is known under a number of 
names such as Syndrome X, Deadly Quartet and Reaven’s Syndrome.
 
1.2 BACKGROUND TO VITAMIN D 
1.2.1  Biochemistry of Vitamin D  
Vitamin D is part of a group of secosteroid molecules that are traditionally associated with bone 
and calcium metabolism, rather than cardiometabolic physiology for example. Five forms of vitamin 
D are known, namely D1 to D5 (See Table 1.1).  Vitamins D2 and D3 are the most studied forms.
5   
Vitamin D and its metabolites can be divided into two families of secosteroids, the cholecalciferols 
and ergocalciferols.   
Cholecalciferol (vitamin D3), the parent compound of the form naturally occurring in humans, is 
produced in the skin on exposure to sunlight. The ultraviolet B (UVB) [290-315nm] portion of 
sunlight converts 7-dehydrocholesterol to previtamin D3.  Previtamin D3 undergoes thermal 
isomerisation from vitamin D3.
6 
Vitamin D2 (ergocalciferol) is derived from ergosterol. Ergosterol is a sterol produced by some 
phytoplankton, invertebrates, and fungi. These organisms use ergosterol and sunlight to produce 
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vitamin D2. Because they lack ergosterol, land plants or vertebrates cannot produce vitamin D2. 
The action of light causes ring cleavage to yield an intermediate pre-ergocalciferol (plus lumisterol 
and other related congeners), which rearranges under thermal conditions to ergocalciferol.2
 
Vitamin D2 is different from D3 in that D2 has a double bond between carbon 22 and carbon 23 and 
a methyl group on carbon 24.2 Both vitamin D2 and D3 can also be consumed in supplements or 
fortified foods. 
Unless otherwise indicated, when vitamin D and its metabolites are written without a subscript, 
both families of vitamin D, ergocalciferols and cholecalciferols, are being included.6
 
Table 1.1 Vitamin D and its metabolites  
NAME ABBREVIATION GENERIC NAME SERUM 
CONCENTRATION 
Mean ± SD 
VITAMIN D 
(total for Vit D2 and D3) 
D CALCIFEROL 1.6 ± 0.4ng/ml  
4.1 +- 1.0nm/l 
VITAMIN D2 D2 ERGOCALCIFEROL  - 
VITAMIN D3 D3 CHOLECALCIFEROL - 
25-Hydroxyvitamin D 25(OH)D CALCIFEDIOL 26.5 ± 5.3ng/ml 
66.25 +- 13.25nm/l 
1,25-Dihydroxyvitamin D 1,25(OH)2D CALCITRIOL 34.1 ± 0.4pg/ml 
81.84 +- 0.96nm/l 
24,25-Dihydroxyvitamin D 24,25(OH)2D - 1.3 ± 0.4ng/ml 
3.12 +- .96nm/l 
25,26-Dihydroxyvitamin D 25,26(OH)2D - 0.5 ± 0.1ng/ml 
1.2 +- 0.24nm/l 
Table modified from Basic and Clinical Endocrinology.
7 
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1.2.2 Vitamin D Metabolism 
Vitamin D metabolites are transported in the blood bound mainly to vitamin D–binding protein (DBP) 85% 
and albumin 15%. The conversion of vitamin D to 25-hydroxyvitamin D occurs mainly in the liver with the 
help of the enzyme 25-hydroxylase. The kidney mainly controls vitamin D metabolism. In a rate limiting step 
the kidneys convert 25-hydroxyvitamin D to its active form 1,25(OH)2D3 by 1 alpha-hydroxylase. Production 
of 1,25(OH)2D3 in the kidney is stimulated by parathyroid hormone (PTH) and is inhibited by high blood 
levels of calcium and phosphate.
2
  
 1,25(OH)2 vitamin D is the active form of vitamin D. This binds to vitamin D specific receptors. This receptor 
is referred to as VDR and is part of the class 2 steroid hormones. Similar receptors are the thyroid hormone, 
retinoid X and retinoic acid receptors. There are certain important domains on this receptor, similar to 
these other receptors. There is the C-domain, which binds DNA, the E-domain which binds ligands and the 
F-domain, which is an activating domain. In humans, the receptor is a peptide, which has 427 amino acids. It 
acts by means of VDRES, the vitamin D responsive elements. These are sequences of nucleotides supported 
by 3 bases. They are found very close to the target gene. The retinoic acid X receptor binds to the 5’arm and 
the VDR to the 3’arm.
viii
 
CYP 24, known as 24 hydroxylase enzyme, causes degradation of vitamin D. This gene is very strongly 
regulated and its own destruction is pre-programmed. This aspect is a vital one in the endocrine system. 
The VDR and the retinoid x receptor form a heterodimer at the VDR element. It also binds other proteins 
necessary for the transcription complex. Essentially an activator is acquired. Three co-activators are known: 
SARC1, SARC2 and DRIP 205. There could be other co-activators and the co-activators could be selective as 
to gene expression. 
After formation of the complex, the DNA bends and there is phosphorylation on serine-205. The initiation or 
suppression of transcription takes place and this relates to which gene is involved.8
  
The vitamin D receptor is widely distributed in enterocytes, osteoblasts, parathyroid gland cells and distal 
renal tubule cells.
4
 They have recently been found in the liver, immune system, prostate, breast, lungs, 
pancreas, skeletal and cardiac muscle.4
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1.2.3 Sources of Vitamin D  
The main sources of vitamin D for individuals are from sunlight exposure, dietary sources and 
supplementation. Exposure to the sunlight and cutaneous synthesis of vitamin D provides 80-90% of vitamin 
D to humans. Solar UVB radiation (wavelength 290-315nm) penetrates the skin and converts 7-
dehydrocholestrol to pre-vitamin D3, this is then converted to vitamin D3. Vitamin D3 intoxication is 
unlikely to be caused by over exposure to sunlight, as any excess previtamin D3 or vitamin D3 is destroyed 
by sunlight.5 If an individual wears minimal clothing and their whole body is exposed to the sun, 1 minimal 
erythermal dose will provide equivalent vitamin D to 250-500ug (10,000-20,000) vitamin D.4 Vitamin D is not 
widely found in foods and mainly is present in oily fish (e.g. salmon, mackerel, sardines and herring) and 
some fortified foods for example milk and juices in the United States of America (USA) and Canada where 
fortification provides >100IU per 8oz serving. Daily vitamin D obtained from standard dietary sources is 
2.5ug (100IU), and fortified foods provided up to 5-10ug (200-400IU) of vitamin D per day.4 In South Africa 
mainly margarine is fortified. 
1.2.4 Recommended Vitamin D Intake  
Over the past several years, the increased interest in vitamin D and its proposed health benefits has led to 
an increasing frequency of vitamin D testing and increase in the use of vitamin D supplements.  
The USA and Canadian governments felt that much of this practice was not based on scientific evidence.9 In 
response the assembled a committee of experts to assess the growing body of research on vitamin D and 
give guidelines regarding vitamin D intake.9 
The IOM committee increased the recommended dietary allowance (RDA) from the 1997 IOM report, which 
lacked sufficient evidence for development of the RDA and had to instead estimate the adequate intake 
(AI).
13
 
 The IOM based its recommendations for vitamin D intake using bone health as an indicator.14 Extra skeletal 
indicators were not used for Dietary Reference Intake (DRI) development because of insufficient evidence of 
causality, inconsistency in the evidence, or inability to develop a dose response relationship.  
The IOM concluded that 50nmol/L is optimal for bone health.Error! Bookmark not defined. This serum level 
orresponds to an intake of 25-hydroxyvitamin D level corresponding is 600IU/d. The adequate intake (AI) 
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was set at 400IU/d for infants and the RDA was set at 600IU/d for children and adults and 800IU/d for those 
over 70 years of age. This intake in the elderly is predicted to result in a serum 25-hydroxvitamin D level of 
73nmol/L. The “no observed adverse event level “NOAEL” was proposed to be 10,000IU/d. However, the 
upper limit (UL) was set lower at 4 000IU/d, corresponding to a serum vitamin D level of 125nmol/L.  
As mentioned earlier, the IOM committee followed an evidence-based approach and set a RDA-intake value 
of 50nmol/L based on the literature for skeletal health. However, The Endocrine Society and other experts 
are of the opinion that the cut off point for serum vitamin D adequacy is over 75nmol/L.Error! Bookmark not 
defined. By accepting the higher cut off points, a so-called “epidemic” of vitamin D inadequacy has been 
created. 
To further add to the controversy when the IOM recommendations were published and stated that using 
the 50nmol/L as a cut-off most Americans were receiving enough vitamin D, the most recent data from the 
National Health and Nutrition Examination survey (NHANES; 2005 to 2006) had not been published 
yet.Error! Bookmark not defined. In this survey it was found that the mean 25(OH)D vitamin D levels were 
49.7nmol/L. Thirty one percent of non-Hispanic whites were vitamin D deficient using the 50 nmol/L and 
below cut off, whereas 63% of Hispanics and 82% of non-Hispanic blacks were vitamin D deficient. 
The Endocrine Society also assembled recently to provide clinicians with guidelines for the evaluation, 
treatment and prevention of vitamin D deficiency.15 Their emphasis was on the care of patients who are at 
risk for deficiency.  
Some confusion has also arisen for clinicians and patients as a result of the RDA being used as different 
goals. The IOM report regards the RDA as the target for vitamin D intake. By contrast the Endocrine Society 
recommends the RDA values as the minimum. A reason for this may be that the patients to whom the 
Endocrine Society is addressing their recommendations are at risk for deficiency, making a higher dose of 
vitamin D necessary. The recommendations published in the guidelines are contrasted with those in the 
IOM report and identified as suggestions for patient care rather than recommended actions for the healthy 
population.9,Error! Bookmark not defined.,Error! Bookmark not defined. 
It is uncommon to see hypervitaminosis D. It can be caused by over supplementation. The symptoms of 
hypervitaminosis D are related to hypercalcaemia and present as loss of appetite, nausea and vomiting, 
polyuria, polydipsia, weakness, nervousness, pruritis and kidney failure.5 
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1.2.5 Serum Levels of Vitamin D 
The major circulating metabolite of vitamin D is serum 25(OH) vitamin D. Its levels reflect sunlight exposure 
and dietary intake. Serum 1,25(OH)2 vitamin D levels can be normal or even elevated in patients with 
vitamin D deficiency.5 There was previously  no consensus on the optimal levels of 25(OH) vitamin D as 
measured in serum. The IOM has established guidelines for clinicians regarding vitamin D levels, vitamin D 
deficiency is defined by the IOM as a 25-hydroxyvitamin D level of less than 30nmol/L.
  
Vitamin D 
inadequacy as between 30-50nmol/L and vitamin D greater than 125nmol/L as the upper limit of normal.9
  
 
The Endocrine Society clinical practice guidelines define vitamin D deficiency as 25 hydroxyvitamin D below 
20ng/ml (50nmol/L) and vitamin D insufficiency as a 25 hydroxyvitamin D of 21-29 ng/ml (52,5-72,5 
nmol/L).
15  
Vitamin D deficiency or insufficiency affects approximately 1 billion people worldwide.6 Several factors 
increase the risk of vitamin D deficiency. These include the elderly, increased skin pigmentation, 
institutionalized or homebound status, increased distance from the equator, winter , clothing (which 
decreases the amount of skin surface exposed), the use of sunscreen, air pollution, cigarette smoking, 
obesity, malabsorption, renal disease, liver disease and medications.5   
Statistics from several studies show how winter affects serum levels of vitamin D. In one study in the USA, 
36% of young healthy free living adults aged 18-29 years had vitamin D deficiency at the end of winter.5 In 
other studies in the USA 42% of 15-49 year old black girls plus woman had vitamin D deficiency i.e. serum 
vitamin D levels below 20ng/ml.6 A study in a Boston hospital reported that 32% of healthy students, 
physicians and residents presented with a vitamin D deficiency, despite drinking a glass of milk, taking a 
multivitamin containing vitamin D daily and eating salmon at least once a week.6 
According to several studies, 40-100% of USA and European elderly men and women still living in the 
community (not in nursing homes) are deficient in vitamin D.6 Studies in Victoria, New South Wales and 
Western Australia revealed that older people who are institutionalized or housebound are particularly at 
risk of vitamin deficiency. Eighty percent of women and 70% of men living in hostels or nursing homes were 
frankly deficient in vitamin D, and overall 97% of the surveyed people had a 25 (OH) vitamin D level below 
the median value of the healthy reference range.
ix
 Data from the National Nutritional Survey of New 
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Zealand showed that 1.6% of males over 65 years and 5.8% of females had blood levels below 17.5nmol/L 
for serum 25(OH)D and that 20.5% of men and 39.6% of woman had levels below 37.5nmol/L. This survey 
did not include institutionalized people.
 
Plasma 25(OH) vitamin D levels are inversely related to menopausal 
status. More than 50% of post menopausal women taking medication for osteoporosis had suboptimal 
levels of 25 (OH) vitamin D, with levels below 30ng/ml (75nmol/L). Studies in the United Kingdom and South 
Africa reported that 13% to 33% of patients with hip fractures had histological evidence of osteomalacia 
that may have been caused by chronic vitamin D deficiency.
10
 People living in sunny climates and who are 
exposed to sunlight tend to have higher levels of vitamin D. However, even countries such as New Zealand 
and Australia, which have plenty of sunshine, as well as latitudes with sufficiently moderate climates to 
allow some endogenous synthesis throughout the year, are diagnosing cases of hypovitaminosis D.
12
 In 
sunny climates where most of the skin is shielded from the sun, such as Saudi Arabia, the United Arab 
Emirates, Australia, Turkey, India and Lebanon, 30-50% of children and adults had 25(OH) vitamin D levels 
under 20ng/ml.6 
1.2.6 Assays for Vitamin D Measurement 
There are several different methods to measure vitamin D levels in blood.  Most laboratories measure 
25(OH) vitamin D levels.  Amongst the private laboratories in South Africa, Lancet Laboratories use the 
chemiluminescence assay.16 Ampath Laboratories use a immunoassay.17 Several types of assays are available 
for measurement as serum 25(0H)D, but the two most common are antibody type methods and liquid 
chromatography-based methods.  There is concern about the performance of these assays. It is generally 
thought that the “gold standard” is liquid chromatography mass-spectrometric detection.  However, these 
methods both measure physiologically relevant parameters, i.e. the total serum 25(OH)D.  There is concern 
about the accuracy of serum 25(OH)D measurements in individual laboratories.Error! Bookmark not defined. 
An International organization, Vitamin D eternal quality assessment scheme (DEQAS) runs a quality 
assurance programme to identify issues of quality control in individual laboratories and helps with their 
corrections.14 
1.3 DESCRIPTION OF THE METABOLIC SYNDROME AND THE ROLE OF VITAMIN D 
1.3.1 Vitamin D and Cardiometabolic Disease  
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Vitamin D has long been known to be vital to bone health.  More recently, vitamin D has been postulated to 
play a role in the risk for malignancy and infections as well as normal immune function and cardiovascular 
health.18 
There is mounting interest in the role of vitamin D in the constellation of metabolic abnormalities grouped 
under the term “metabolic syndrome”, which includes hypertension, dyslipidaemia, abdominal obesity, 
glucose intolerance and type II diabetes.Error! Bookmark not defined.
  
Several systematic reviews have been published looking at the relationship between levels of vitamin D and 
cardiometabolic disorders.  In a review by Parker et al.
19
 they included cross-sectional studies, case-control, 
cohort and randomised controlled trials.  A meta-analysis was performed to assess the risk of developing 
cardiometabolic disorders comparing the highest and lowest groups of serum 25(OH)D.   They found that 
the highest levels of serum 25(OH)D were associated with 43% reduction in cardiometabolic disorders.  This 
finding applied to all outcomes reported: cardiovascular disease, diabetes mellitus or metabolic syndrome. 
In another review by Pittas et al.
20
 they included longitudinal observational studies and randomised 
controlled trials.  They examined the association between vitamin D status, including the effect of vitamin D 
supplementation on cardiometabolic outcomes.   They concluded that the association between vitamin D 
status and cardiometabolic outcomes is uncertain, and that the trials showed no clinically significant effect 
of vitamin D supplementation at the dosages given. In a review by Wang et al.21 prospective studies and 
randomised trials were included.  They felt that vitamin D supplements at moderate to high doses may 
reduce cardiovascular disease.Error! Bookmark not defined.
 
The authors of all the studies concluded by echoing the same sentiment.  In order to make 
recommendations regarding vitamin D supplementation and cardiovascular risk factors adequate 
randomised trials are needed.  These trials need to be conducted in well-defined populations (e.g. pre 
diabetics, pre hypertension or white versus non white persons). The dosages of vitamin D need to be 
optimal and the vitamin D status of the population needs to be specified i.e. deficient versus optimal. 
Low serum 25(OH)D  concentrations have been shown to correlate with impaired glucose tolerance and an 
increased risk of type 2 diabetes, while a correlation between hypovitaminosis D and insulin resistance has 
been identified in pregnant women and obese adolescents.
11
  A 10 year prospective study identified an 
inverse relationship between baseline serum 25(OH)D concentrations and later risk of insulin 
resistance.Error! Bookmark not defined.
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Studies have shown variable results regarding the association between vitamin D levels and the metabolic 
syndrome.  Several studies implicated low vitamin D levels, specifically 25(OH) vitamin D with an increased 
prevalence of the metabolic syndrome.  Other studies show no association between 25 hydroxyvitamin D 
levels and the metabolic syndrome.Error! Bookmark not defined.
,22 ,23 
The mechanism whereby the vitamin D endocrine system is thought to have an effect on the metabolic 
syndrome is via insulin secretion and insulin resistance. Studies have shown that vitamin D and calcium are 
both important in the regulation of insulin secretion from the beta-islet cells of the pancreas.Error! 
Bookmark not defined. Pancreatic beta cells have both receptors for vitamin D and vitamin D dependent 
calcium – binding proteins. This provides evidence for the role of Vitamin D in the regulation of beta cell 
insulin secretion.
  
Deficiency of both calcium and vitamin D leads to impaired insulin secretion.  
This hypothesis has been documented in both rat and human studies.24,
25
 One of the possible explanations 
is that vitamin D maximizes glucose-induced insulin release by stimulation of islet cell calcium uptake. The 
vitamin D endocrine system is also thought to be important for insulin synthesis. Vitamin D deficiency is 
accompanied by decreased pancreatic preproinsulin mRNA which is reversible by vitamin D treatment.
 
 
Vitamin D has also been linked to insulin sensitivity. Both studies in vitro and in rats have shown an effect 
on insulin sensitivity.Error! Bookmark not defined. 
1.3.2 The Contribution of Vitamin D Deficiency to Disease States 
Since the individual components of glucose intolerance, hypertriglyceridaemia, obesity and hypertension 
are associated with low 25-hydroxyvitamin D levels, it is not surprising that 25-hydroxyvitamin D deficiency 
is also associated with the metabolic syndrome in several studies.6 
1.3.2.1 Vitamin D and Obesity
 
Different theories are advanced as to the mechanism of the association of low 25(OH) vitamin D serum 
levels with the diverse parts of the metabolic syndrome. 
Foss 
26
 suggests that obesity as well as the metabolic syndrome have evolved in order to deal with the 
winter environment, as described below.  
The concept of an adipostat, by which weight is centrally controlled and maintained, is commonly proposed. 
This ensures that body weight is maintained at a fixed level by balancing energy intake and output by means 
Stellenbosch University  http://scholar.sun.ac.za
 11 
 
of several homeostatic mechanisms. Consequently if body size increases, surface area to volume ratio 
decreases. This result in less heat loss. More fat can obviously be stored in a bigger body when food is 
scarce. All of this means that a bigger body improves survival chances in winter. This can be taken further to 
explain each of the parts of the metabolic syndrome. Shivering needs additional fuel in the form of 
carbohydrates, lipids or proteins. Glucose, lipids and triglycerides are all increased in the metabolic 
syndrome.  
There are two types of shivering namely low and high intensity shivering. These rely on type I and type II 
fibres respectively. Glucose transport into type II fibres is not as dependent on insulin as type I. Insulin 
resistance would favour preferential delivery of glucose to the type II fibres. This would enable the shivering 
response. The cause of this winter response might be a fall in Vitamin D levels. Vitamin D in turn is 
synthesised as a result of UVB radiation. At higher latitudes, UVB decreases in autumn and almost 
disappears in winter. 
There is a theory that vitamin D evolved in primitive organisms as a receptor to signal changes in sunlight 
levels. The hypothalamus can sense the level of vitamin D and consequently raise the set point of the body 
mass.
26 
Another mechanism whereby vitamin D levels are decreased in overweight individuals is through 
sequestration of vitamin D in the adipose tissue.
6 
Sneve et al.
27
 enrolled four hundred and forty five healthy, overweight and obese participants. They were 
randomized into three groups: Those given 20 000IU cholecalciferol twice a week, or 20 000IU once a week 
plus placebo, or placebo twice a week for 12 months. All participants were given 500mg calcium. At the end 
of the 12 months period it was established that cholecalciferol supplementation did not lead to more 
weight reduction in overweight and obese people compared to placebo.Error! Bookmark not defined. 
There are varying results when examining the studies looking at the effects of vitamin D supplementation 
on weight. Sneve et al.Error! Bookmark not defined. referred to a study by Lijunghall et al. on 65 men aged 
61-65 years, in which there was a significant weight loss of 1.1 kg in the group given 0.75ug alphacalcidol 
when compared to the placebo group over a 12 week period.
 
Lind et al.
28
 noted a small but significant 
weight loss of 0,9 kg over 18 months in a group of 14 middle aged men treated with 2 micrograms of 
alphacalcidol daily over 18 months.  
In contrast a study by Nilas and Christiansen, cited in Sneve et al.Error! Bookmark not defined., that included 
Stellenbosch University  http://scholar.sun.ac.za
 12 
 
In contrast a study by Nilas and Christiansen, cited in Sneve et al.Error! Bookmark not defined., that included 
238 post menopausal women, treated for 1 year with either 2 000IU cholecalciferol, 0.25ug alphacalcidol or 
0.25 – 0.50ug calcitriol, reported no effect on the body weight when compared with placebo.  
Zittermann et al.
29
 observed the association between low 25-hydroxyvitamin D (<43nmol/L) and obesity. It 
has been observed that 1.25(OH)2D3 levels are also low in obese individuals. Higher calcitriol levels have 
been shown to be beneficial to cardiac muscle cells and to vessels. In those patients who are at a higher risk 
of cardiovascular mortality, calcitriol concentrations less than 60pmol/L are independently associated with 
poor clinical outcomes.  
Zitterman et al.Error! Bookmark not defined. looked at vitamin D supplementations’ beneficial effects of 
weight loss on cardiovascular disease risk markers. The study showed that a daily vitamin D supplement of 
3332IU cholecalciferol beneficially influenced some traditional and non-traditional cardiovascular disease 
risk factors. These included: blood pressure, cholesterol, C-reactive peptide, tumour necrosis factor – alpha, 
interleukin-6, glucose, HbA1c and pro-insulin, but had no effect on weight loss in overweight plus obese 
subjects. The beneficial biochemical effects were independent of the losses in body weight, fat mass and fat 
mass in the abdominal region.
 
Boon et al.
30
 examined the effects of a seven day oral supplementation with 2 000IU cholecalciferol per day 
on energy and substrate metabolism and adipose tissue gene expression of proteins related to energy and 
metabolism. No differences in resting metabolic rate or fat oxidation were observed. There were also no 
differences in gene expression of five of the genes involved in the lipogenic and lipolytic pathways.
 
Another pathway whereby supplementation with vitamin D could affect weight is dependent on calcium 
and PTH as key determining factors. The benefits of a high calcium diet have been observed, and increase in 
the loss of fat mass and increased energy expenditure have been noted in higher calcium diets.Error! 
Bookmark not defined. In vitro plus in cultures of human adipocytes,1,25-(OH)-D3 has been shown to cause 
increases in intracellular calcium. This increased intracellular calcium in the adipocytes increases lipogenesis 
and inhibits lipolysis. Serum 1,25-(OH-D3 responds to changes in dietary calcium intake. Therefore by 
decreasing dietary calcium intake an accompanying increase in serum 1,25-(OH)-D3 will occur resulting in an 
increase in intracellular calcium and fat accumulation.Error! Bookmark not defined.
 
 
On looking at in vitro studies PTH has also been found to increase intracellular calcium levels, which in turn 
may induce fat accumulation. If Vitamin D is administered this would result in a decrease in PTH levels, the 
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ultimate effect on adipocytes following Vitamin D supplementation would depend on the relative 
importance of reducing the PTH level versus increasing the 1,25-(OH)D3 level.Error! Bookmark not defined. 
 
 
1.4.2.2 Vitamin D and impaired glucose tolerance or Type II Diabetes 
The second component of the metabolic syndrome associated with hypovitaminosis D is impaired glucose 
tolerance or Type II diabetes.  
When considering what role vitamin D plays in diabetes mellitus a number of mechanisms need to be 
considered. These include chronic inflammation, dysfunction of pancreatic B-cells and resistance to insulin 
peripherally.5 
In experiments, vitamin D receptors have been shown to exist in the pancreas islets. Further, vitamin D 
dosing in Vitamin D deficient animals raises the secretion of insulin.
31
 
In vitamin D receptor knockout mice the rate of insulin secretion after a glucose challenge was impaired 
despite the basal insulin rate not being changed. Pancreatic intracellular calcium is an important stimulus 
for the secretion of insulin. This is affected by vitamin D deficiency. 
The expression of insulin receptors as well as the response of insulin for glucose transport has both been 
shown to be dependent on vitamin D. Thus, the role of vitamin D in secretion and sensitivity of insulin is 
well demonstrated.Error! Bookmark not defined. 
Pancreatic B-cell dysfunction, peripheral tissue resistance to insulin and chronic inflammation appear to be 
possible mechanisms for the role of vitamin D in diabetes mellitus.
3 
Experimentally, vitamin D receptors 
have been identified in pancreatic islets and administration of vitamin D  increases insulin secretion in 
vitamin D-deficient animals.
28 
Basal insulin rate was not altered in vitamin D receptor-knockout mice, but 
insulin secretion rate after a challenge with glucose diet was impaired in vitamin D deficiency.  Vitamin D 
may affect intracellular calcium levels in pancreatic cells, which is an important stimulus for insulin 
secretion.   Vitamin D has also been shown to control insulin receptor-expression and insulin responsiveness 
for glucose transport, establishing its role in insulin secretion and sensitivity.5  
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There are a significant number of studies looking at vitamin D supplementation and its effects on fasting 
blood glucose, glucose tolerance and insulin sensitivity.
5
  The results are variable.  This variability has been 
postulated to be due to ethnic differences or vitamin D receptor gene polymorphisms.5  
Parekh et al.Error! Bookmark not defined. echoed this sentiment in his review paper, citing several studies 
conducted in glucose tolerant as well as glucose intolerant human subjects to evaluate the role of vitamin D 
on insulin sensitivity, insulin secretion and glycaemic status.  The outcomes have been inconsistent in these 
investigations.  Among publications that evaluated the role of vitamin D supplementation in patients with 
glucose intolerance and Type 2 diabetes, only one report including women with gestational diabetes 
mellitus showed a significant decrease in blood glucose levels.Error! Bookmark not defined.   
In a study by Patel et al.
32
 in which conventional vitamin D treatment improved, but did not optimise serum 
25(OH)D no improvements in glycaemic, insulin sensitivity or the lipid profile were seen.Error! Bookmark not 
defined.
 
Parekh et al.Error! Bookmark not defined. are in agreement with the paper by Vanga et al.5 in which they 
stated that vitamin D receptor gene polymorphisms may affect the glycaemic response to vitamin D and 
ethnic variation in vitamin D receptor polymorphisms (a well described entity) is responsible for the varied 
responses seen. 
A small study involving 10 women with Type 2 diabetes treated with cholecalciferol 1332 IU daily for one 
month showed increased first-phase insulin secretion.  Fasting and post-change (75g glucose) insulin levels 
were also decreased with increased 25(OH) vitamin D concentrations in 142 elderly non-diabetic.Error! 
Bookmark not defined.
 
 In a trial by Witham et al.33
 
looking at a group of Type 2 diabetics, who were randomized into 3 groups of 
single dose 100,000, 200,000 IU of vitamin D3 and placebo, the effects of raising 25(OH)D levels on 
endothelial function, blood pressure and markers of glycaemic control were examined.  High dose vitamin 
D3 had no significant effect on HbA1c or insulin resistance.  Systolic blood pressure was improved and B-
type natriuretic peptide levels improved.  
This study highlighted the fact that the positive effects of vitamin D on insulin resistance have been 
documented in a few studies where the patients have been pre diabetic. In contrast, in patients with Type 2 
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diabetes administration of vitamin D has not had a positive effect on insulin resistance or glycaemic 
control.35  
In another trial by Nagpal et al.34 100 healthy, middle-aged centrally obese men were given short-term 
vitamin D supplementation (3 doses of vitamin D3 fortnightly, 120,000IU each) to determine its effect on 
insulin sensitivity. The authors concluded that vitamin D supplementation increased the oral glucose insulin 
sensitivity index in centrally obese men.   The response was better in subjects with lower serum 25(OH)D 
concentrations and in those with greater central adiposity. Nagpal and his colleagues felt there was a 
paucity of intervention trials on the effect of vitamin D supplementation on insulin resistance or glucose 
metabolism.   In addition the available trials were conducted using small sample sizes and in different 
clinical settings, using different agents, regimens and outcome parameters therefore results documented 
were inconsistent.34
 
 
In the Women’s Health initiative trial calcium and vitamin D3 were randomly assigned to postmenopausal 
women.  Among 33,951 participants without self-reported diabetes at baseline, new diagnoses of diabetes 
treated with oral hypoglycaemic agents or insulin were ascertained by treatment assignment.   The effects 
of the intervention on fasting measurements of glucose, insulin and insulin resistance were examined 
among a subset of participants.  The Women’s Health Initiative was a good opportunity to address the 
effect of calcium plus vitamin D supplementation on the development of diabetes because of its large size, 
placebo control and relatively long duration of treatment and observation.   In conclusion, the study found 
that calcium plus vitamin D3 supplementation did not reduce the risk of developing diabetes.35
  
To date the Women’s Health initiative is the largest trial on vitamin D supplementation.  This trial reported 
no statistically significant effects for all cardiometabolic outcomes examined.  Notable problems with this 
trial included: a relatively small dose of vitamin D was used (400IU/d), and participants in both intervention 
groups were permitted to receive supplemental vitamin D.  There were difficulties with adherence over a 7 
year period.Error! Bookmark not defined.
 
The vitamin D dosage of 400IU used increased median plasma 25(OH) vitamin D levels from 42.3 nmol/L to 
on 54.1 nmol/L.  Extrapolating these data to achieve 25(OH) vitamin D levels about 75nmol/L, the 
recommended level for several health outcomes, would require supplementation of at least 1000IU/d to 
determine whether improvements in vitamin D status may prevent cardiovascular disease.22 A protective 
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effect of vitamin D supplementation on cardiovascular disease is possible, but a moderate to high dose may 
be needed.  
The evidence for the role of hypovitaminosis D in impaired glucose tolerance and Type II diabetes is limited.  
There is a lack of large randomized controlled trials.  The trials that have been done show inconsistent 
results.  Type II diabetes is a condition which is increasing in epidemic proportions.7   
If vitamin D has a preventative role to play in its aetiology and course, this would have significant 
implications.  The need for large well-conducted randomised controlled trials is clearly evident.  
 
 
1.4.2.3 Vitamin D and blood pressure 
An inverse relationship between vitamin D and hypertension has been documented. In vitro studies showed 
that 1,25-dihydroxyvitamin D inhibits renin expression in the juxtaglomerular apparatus and blocks the 
proliferation of vascular smooth muscle cells, which could result in changes in systemic blood pressure.36 
This hypothesis was reinforced by Li et al. (in Forman et al)
36
 who showed that 1,25-hydroxyvitamin D 
inhibits renin expression in mice and inhibits the growth of cultured vascular smooth muscle cells. The 
association between vitamin D and hypertension may be mediated via the renin-angiotensin system and the 
vasculature.36 In vitamin D deficient subjects replacement with vitamin D significantly improved flow-
mediated dilation of the brachial artery, suggesting a role of vitamin D in the sensitivity of vascular smooth 
muscle cells.5
  
Geographical location plus latitude seem to play a role in the relationship between vitamin D and blood 
pressure. In the INTERSALT study, which studied more than 10 000 participants worldwide, both systolic and 
diastolic blood pressure was significantly and positively associated with distance from the Equator.36 In 
keeping with this study, it has been noted among Africans that those residing in northern regions have 
higher blood pressure than those residing closer to the Equator. Seasonal variation of blood pressure within 
the same population has also been documented.36
  
In a smaller study, 18 hypertensive patients participated in a randomized controlled trial. One group 
received repeated exposure to artificial UVA radiation (which cannot produce Vitamin D3) and the second 
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group received UVB radiation (which leads to cutaneous Vitamin D3 synthesis). The UVB treatment group 
showed an average of 6mm Hg decrease in both systolic and diastolic blood pressure and a 180% increase in 
serum 25(OH)D levels versus the group exposed to UVA, who showed no change in serum 25(OH)D levels or 
blood pressure.37
  
Pfeifer et al.38 conducted a randomised, placebo-controlled, double blind trial of 148 elderly women in 
which one group was given 1200mg calcium plus 800IU vitamin D3 and the second group 1200mg calcium 
daily. The trial took place over an 8 week period. At the end of the trial the intervention group showed a 
decrease in systolic blood pressure of 9.3% (p = 0.0).  Sixty participants in the vitamin D3 and calcium group 
compared to 35 participants in the calcium group, showed a decrease in systolic blood pressure of 5mm Hg 
or more (p=0,04). There was no change in diastolic blood pressure. The authors concluded that 
supplementation with vitamin D3 and calcium is more effective in reducing systolic blood pressure than 
calcium alone.38
 
 
In a large prospective study in which more than 200 000 men and women from the two Nurses Health 
studies and the Health Professionals follow up study were studied, it was concluded that higher intake of 
vitamin D was not associated with a lower risk of incident hypertension.39  
In the Nurses Health Study I, 27 084 participants reported developing hypertension. Vitamin D intake was 
not associated with a lower risk of hypertension.
 39 In the Nurses Health Study II, 7 372 participants reported 
developing hypertension. In this study there was also no association between vitamin D intake and the risk 
of hypertension. Women whose intake of vitamin D was <200IU/d had no increased risk compared to those 
whose intake was higher than 1000IU/d (multivariable RR, 1.03; 95% CI 0.85 to 1.25).39 In the Health 
Professionals follow up study 8 834 men developed hypertension, and no association between vitamin D 
and hypertension was documented when men who consumed >100IU/d were compared with men who 
consumed <200IU/d (multivariable RR, 1.06; 95% CI 0.90 to 1.22).39  
Pfeifer et al.38 hypothesized that using calcium plus vitamin D3 for a short while may improve blood 
pressure as well as secondary hyperparathyroidism more effectively than calcium alone. 
Forman et al.36 postulated that the difference in outcomes between the different studies may be explained 
by the fact that some studies recruited participants from the general population,
39 
whereas others
 
recruited 
only vitamin D deficient subjects.
38
 To give us an estimation of the plasma 25-hydroxyvitamin D levels in the 
adult population we can look at the levels from the National Health and Nutrition Examination Survey III 
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data. The mean 25-hydroxyvitamin D levels in white adults over the age of 30 years were 28ng/ml, which 
might be an approximation of the mean level in the observational study.
39
 In the interventional study,
38
 the 
mean 25-hydroxymvitamin D level increased from 10.2 ng/ml at baseline to 25.9 ng/ml after 
supplementation. 
These findings suggest that a threshold may exist, and vitamin D deficiency may have detrimental effects on 
blood pressure, whereas higher levels of vitamin D may not have such a marked effect on blood pressure.
36
 
In a systematic review and meta-analysis by Witham et al.40 a small reduction in blood pressure using 
vitamin D compounds was seen in hypertensive patients but no effect was seen in normotensive patients. 
The authors of the review concluded that the evidence was not sufficient to make recommendations for the 
use of vitamin D in clinical practice as a tool for lowering blood pressure.
40
 
1.3.2.4 Vitamin D and lipid profile 
The final component of the metabolic syndrome to be examined is the serum lipid profile. There are very 
few studies looking at the relationship between vitamin D3 and lipid parameters. Most of the studies have 
either been done on animal models, or have used dosages of vitamin D3 that have been higher than that of 
the normal therapeutic range. The results have also been inconclusive.  
One study by Heikkinen et al.
 41
 looked at the long term effects of hormone replacement therapy (HRT) and 
vitamin D3 on the concentration of serum lipids in a population based prospective three year study. Four 
hundred and sixty four women were randomized into four groups: 
• Group 1 received HRT 
• Group 2 received 300IU/d Vitamin D3 
• Group 3 received HRT plus vitamin D3 (dose as above) 
• Group 4 received placebo 
The outcomes after three years showed  positive effects of HRT on lipid parameters, vitamin D3 was 
thought to have unfavourable effects on lipids in this group of postmenopausal women as  vitamin D3  
caused an increase in serum LDL cholesterol levels. The positive effects of HRT were diminished when 
combined with vitamin D3.
41
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Lind et al.42 in a cross-sectional population based study looked at the relationship between vitamin D and 
various cardiovascular risk factors in 34 middle aged men. An inverse relationship was found between 
vitamin D, blood pressure and markers of lipid plus insulin metabolism.42 The authors
 
put forward a 
hypothesis that although the possibility exist that active vitamin D might have yet unknown direct effects on 
glucose and lipid metabolism, low levels of active vitamin D may be involved in the aetiology of the 
metabolic syndrome as a whole. 
Low levels of vitamin D may be only a marker for a yet undefined abnormality resulting in abnormal blood 
pressure, lipid, glucose and mineral metabolism, and in active vitamin D production. One theory postulated 
is that of altered cell membrane fluidity.42
 
Vitamin D levels may be increased by the use of statins. This could explain the multiple non-cholesterol 
effects of these drugs. The possible mechanisms are as follows: 
3-Hydroxy-3-methylglutaryl coenzyme A (HMG-Co-A) reductase is inhibited by the statins. This causes 
increased 7-dehydroxycholesterol. This in turn is converted by sunlight to 25-hydroxycholecalciferol.5  
Clearly, all of the above provides evidence both for and against the role of vitamin D in the metabolic 
syndrome.  
 
1.4 HEALTH CLAIMS 
Over the past few years there has been a marked interest in both the scientific and lay media of the health 
effects of vitamin D. 
The proposed health benefits attained when taking vitamin D supplementation come in an era when similar 
claims regarding antioxidant vitamins and folic acid supplementation were unsubstantial. The use of beta-
carotene and vitamin E supplements (two antioxidant vitamins that were believed to be safe), showed an 
increase in mortality in randomised controlled clinical trials.43 
When using vitamin supplements such as vitamin D in areas beyond bone and skeletal health, For example; 
cardio-metabolic cases, well-conducted studies documenting both benefits and harms are needed. 
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In one systematic review done by Pittas et al.
21
 on observational studies, the association between serum 
levels of vitamin D and cardiometabolic outcomes was uncertain. Three of six analyses reported a lower 
incident diabetes risk in the higher versus the lowest vitamin D status groups. Eight randomised controlled 
trials found no effect of vitamin D supplementation on glycaemia or incident diabetes. In meta-analysis of 3 
cohort studies, lower 25-hydroxyvitamin D concentration was associated with incident hypertension. In a 
meta-analysis of 10 randomised controlled trials vitamin D supplementation non-significantly reduced 
systolic blood pressure and did not affect diastolic blood pressure.
21
 The range of dosages used in these 
trials ranged from 400 to 8571IU/d and the study participants were heterogeneous. 
In a second systemic review done by Wang et al.
21 
also on 17 observational studies, the association between 
vitamin D and calcium supplementation and the prevention of cardiovascular events was examined. The 
results showed consistent reductions in cardiovascular disease mortality among adults who received 
vitamin D supplements. Five of these six studies were conducted among patients receiving dialysis and the 
generalisability of the results to healthy adults is therefore uncertain.
21
 
The effect of vitamin D supplements on cardiovascular disease, diabetes, dyslipidaemia and hypertension 
remain uncertain. However, the available evidence in favour of vitamin D supplementation is far more 
promising than for other vitamin or mineral supplements.43 
 1.5 WHY IT IS IMPORTANT TO DO THIS REVIEW   
Evidence-based decision-making should been important concept in the practice of all healthcare 
professionals.  Sacket and Haynes et al.44 defined evidence-based medicine as a “conscientious, explicit and 
judicious use of current best evidence in making decisions” where conscientious means evidence is relevant 
and is applied consistently, judicious means evidence is combined with clinical expertise to obtain a balance 
of risk and benefit for the patient, and current best evidence means that the best type of evidence for the 
specific type of question (e.g. randomized controlled trials for questions on prevention and treatment), 
within the context of the totality of the body of evidence  (i.e. drawing on systematic review methods), is 
used..
 
According to the American Heart Association, almost 25% of Americans are affected by the metabolic 
syndrome.  There are currently no statistics available for the prevalence of the metabolic syndrome in South 
Africa.  A single paper was published looking at the prevalence of the syndrome in a small group of 
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corporate executives in 2007. Using the ATPIII criteria, 31% of the group was diagnosed as having the 
metabolic syndrome.
45
 The limitations of this study include population bias as there was no inclusion of any 
segment of the rural population of South Africa. 
This review would be useful for any patient suffering from the Metabolic Syndrome or any of the individual 
components of the Metabolic Syndrome and practitioners treating such patients. Currently there are no 
systematic reviews looking at the influence of Vitamin D deficiency on the metabolic syndrome. This review 
will therefore provide some evidence – based material as to the use of Vitamin D in the metabolic 
syndrome.  
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1.6 CONCEPTUALISATION  
The influence of vitamin D supplementation on components of the metabolic syndrome was examined in 
this systematic review, as illustrated in Fig. 1.1:  
• Etiological causes of vitamin D deficiency (background literature review) 
• Etiological factors associated with the metabolic syndrome are indicated as genetic predisposition 
and unhealthy lifestyle (background literature review) 
• The individual components that make up the metabolic syndrome are obesity, hypertension, 
dislipidaemia and impaired glucose tolerance (background literature review) 
• The effect of vitamin D deficiency on the components of the metabolic syndrome measured by waist 
circumference, BMI, blood pressure, lipid profile, glucose profile, pro-inflammatory markers and 
prothrombotic markers (systematic review of randomised controlled trials)  
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Figure 1.1 Conceptual Diagram of Vitamin D and the Metabolic syndrome 
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1.7 DESCRIPTION OF THE INTERVENTION   
Trials were considered for inclusion in this systematic review if they compared the effect of vitamin D at any 
dose, duration and route of administration versus placebo or no intervention. In addition, vitamin D may 
have been administered as monotherapy or in combination therapy. Studies were excluded if they used 
fortified foods as intervention. 
1.8 HOW THE INTERVENTION MIGHT WORK 
Vitamin D supplementation may affect each of the individual components of the metabolic syndrome: 
1.  Obesity - increased weight and loss 
2.  Blood pressure – decrease systolic, diastolic blood pressure 
3.  Cholesterol – improve profile 
4.  Glucose – decreased serum glucose 
        - decreased insulin resistance 
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CHAPTER 2:  METHODOLOGY  
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2.1 RESEARCH QUESTION 
What is the influence of Vitamin D2 and D3 supplementation, compared to placebo or no intervention, on 
the components of the metabolic syndrome (raised BMI, hypertension, dislipidaema, glucose intolerance) in 
vitamin D deficient/ insufficient adults? 
2.2 OBJECTIVES   
To assess the influence of vitamin D2 and D3 administration in treating and preventing components of the 
metabolic syndrome in various population groups.          
2.3 CRITERIA FOR CONSIDERING STUDIES FOR THIS REVIEW   
2.3.1 Types of Studies   
Randomised controlled trials investigating the effect of vitamin D supplementation on components of the 
metabolic syndrome. 
2.3.2 Types of Participants   
Participants who met the following selection criteria were included: 
2.3.2.1 Inclusion criteria 
• Adult participants (aged 18 years and older) including the elderly 
• All race groups  
• Patients diagnosed with any one or more of the components of the metabolic syndrome (Table 2.1). 
Drug treatment for elevated serum triglycerides, reduced HDL-cholesterol levels, hypertension or 
elevated blood glucose levels was considered an alternate indicator of the relevant diagnostic 
criteria of the metabolic syndrome. In addition, studies that used population and country specific 
definitions for cut-off points that differed from those in Table 2.1 were also considered for inclusion.  
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• Subjects were considered for inclusion in the study if there 25(OH) vitamin D levels were less than 
80nmol/L. 
• Only studies for which full text articles could be obtained, were included. 
 Table 2.1: Diagnostic criteria of the metabolic syndrome.
61
  
IDF NCEP WHO AACE 
Diagnosed if glycaemia is 
abnormal and 2 
additional criteria are 
present 
Diagnosed if 3 out 
of 5 criteria are 
present 
Diagnosed if glycaemia is 
abnormal and 2 additional 
criteria are present 
Indicates risk factors 
Fasting glycaemia 100-
125 mg/dl or DM2 
Glycaemia 110-
125 mg/dl 
Glucose intolerance DM2 or 
insulin-resistance due to 
HOMA-IR 
Fasting glycaemia 110-
125 mg/dl  > 140 mg/dl 
2 hours after oral GTT 
WC > 94cm M 
WC > 80cm W 
WC > 102 cm M 
WC > 88 cm W 
BMI > 30 and HWR > 0.9 M and 
> 0.85 W 
BMI > 25 and WC > 102 
cm M and WC > 88 cm 
W 
TG > 150 mg/dl or HDL < 
40 M and < 50 W 
TG > 150mg/dl 
HDL < 40 M and < 
50 W 
TG > 150mg/dl or HDL < 35 M 
and < 39 W 
TG > 150mg/dl or HDL < 
40 M and < 50W 
On treatment for SAH or 
BP > 130/85 mmHg 
BP > 130/85 
mmHg 
On treatment for SAH or BP > 
160/90 mmHg 
Microalbuminuria > 20 
mcg/min 
BP > 130/85 mmHg 
HOMA IR > 1.93 = insulin 
resistance 
      
 
AACE = American College of Endocrinology/American Association of Clinical Endocrinologists; BMI = body mass index; 
BP = arterial blood pressure;  DM2 = diabetes mellitus type 2;  GTT = oral glucose tolerance test; HDL= high density 
lipoprotein ; HOMA-IR = homeostasis model assessment;  HWR = hip: waist ratio;  IDF = International Diabetes 
Federation;  M = men;  NCEP = US National Cholesterol Education Program;  SAH = systemic arterial hypertension; TG 
= triglycerides;  W = women; WC = waist circumference; WHO = World Health Organisation. 
2.3.2.2 Exclusion criteria 
• Pregnant/lactating women 
• Kidney and liver disease  
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2.3.3 Types of Interventions   
Trials were considered for inclusion if they compare the effect of vitamin D at any dose, duration and route 
of administration versus placebo or no intervention. Vitamin D may have been administered as 
monotherapy or in combination therapy.  
2.3.4 Types of Outcome Measures   
Studies reporting on the following outcomes were considered for this systematic review. 
2.3.4.1 Primary outcomes   
• BMI 
• Waist circumference 
• Blood pressure 
• Lipid profiles LDL, HDL, triglyceride levels. 
• Blood glucose, insulin profiles, HbA1c, HOMA IR 
• Serum 25(OH)D2 and/or 25-(OH)D3 
2.3.4.2 Secondary outcomes   
• Proinflammatory states fibrinogen, plasminogen, C-reactive protein (CRP) interleukins 
• Prothrombotic state 
• Adverse effects observed 
2.4 SEARCH METHODS FOR IDENTIFICATION OF STUDIES   
2.4.1 Electronic Searches   
2.4.1.1 Search criteria / string 
Search terms were formulated for the condition, the intervention, the use of controls and outcomes. The 
search was performed by a qualified librarian looking for randomised controlled trials using the following 
search string, adapted for individual databases: 
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Topic=((metabolic syndrome OR insulin resistance OR abdominal obesity OR cardiometabolic OR visceral 
obesity)) AND Topic= ((vitamin D OR calcitriol OR 25 ohd OR 25 hydroxyvitamin D OR 25-ohd* OR 25-
hydroxyvitamin D OR 25 (oh)d)) AND Topic=((placebo OR no intervention OR without)) AND Topic=((waist 
circumference OR blood pressure OR hdl OR tg Or lipoprotein OR triglyceride OR glucose OR sugar OR 
insulin OR bmi OR proinflammatory OR prothrombotic OR fibrinogen OR plasminogen OR CRP OR C reactive 
protein OR IL OR interleukin)) 
The librarian performed a literature review using different MeSH Terms including “metabolic syndrome”, 
“insulin resistance”, and “abdominal obesity” in combination with “vitamin D”, “calcitriol”, “25-
hydroxyvitamin D” and “blood pressure”, “waist circumference”, “HDL”, “lipoprotein”, “triglyceride”, 
“glucose”, “sugar”, “insulin”, “BMI”, “proinflammatory”, “prothrombotic”,  “fibrinogen”, “plasminogen”, 
“CRP”, “C reactive protein”, “interleukin” and “IL”. 
This search string was adapted for individual databases by the librarian. 
A search filter in Pubmed restricted the search to randomised controlled trials. 
2.4.1.2 Databases searched 
The electronic search was done in October 2010 at Stellenbosch University Library by the investigator and a 
qualified Librarian. The search was repeated under the same circumstances in May 2012. 
The following databases were used for identification of trials from inception to May 2012:  
• The Cochrane Central Register of Controlled Trials (Central) 
• Medline (accessed via Pubmed)                    
• Science Direct 
• ISI Web Of Knowledge 
• Scopus 
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2.4.1.3 Searching other resources   
• Vitamin D manufacturers were contacted for unpublished trials 
Electronic searches focused on studies published in English databases, but a record was kept of publications 
in other languages so that they could be traced if necessary. 
2.5 DATA COLLECTION AND ANALYSIS   
2.5.1 Selection of Studies   
Two review authors independently screened the titles and abstracts of the electronic search results and 
selected potentially relevant studies using an eligibility form (ADDENDUM A: Part of Data Extraction Form). 
The search was repeated in the same way in May 2012.  Corresponding full-text articles of potentially 
relevant studies were retrieved and used in applying the eligibility criteria. Each of the articles was 
scrutinized to ensure that multiple publications from the same study were included only once. Where 
eligibility was unclear, clarification was sought from the trial authors and the corresponding articles were 
re-assessed. Differences between the reviewers regarding the eligibility results were resolved through 
discussion with other review authors. Studies that did not meet the inclusion criteria were excluded and the 
reasons for exclusion were recorded. 
2.5.2 Data Extraction and Management   
Two review authors independently extracted data on methods, participants, interventions, comparisons, 
study designs, and outcomes from each included study using a pre-designed data extraction form 
(ADDENDUM A) designed specifically for this review. One review author (statistician) also independently 
extracted data relevant for analysis of the effects of intervention. There were no dichotomous outcomes in 
this review. For each continuous outcome, the number of participants randomized, the number of 
participants analysed, the mean and standard deviation (or information to estimate the standard deviation) 
in each treatment group, were extracted. Where necessary, medians and ranges were extracted instead of 
means and standard deviations. Other relevant data extracted were study authors, titles, country and 
setting, source of publication, participant baseline characteristics, ethical clearance, funding source, and 
inclusion and exclusion criteria of participants. The study authors were contacted to request missing data 
and any disagreements were resolved by discussion with other review authors. 
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2.5.3 Assessment of Risk of Bias in Included Studies   
Two review authors independently assessed the risk of bias of the included studies across the following six 
components of the Cochrane Collaboration Risk of Bias tool
60
 (Table 2.2): 
• sequence generation (selection bias) 
• allocation concealment (selection bias) 
• blinding (of participants, personnel, and outcome assessors) (performance and detection bias) 
• incomplete outcome data (attrition bias) 
• selective outcome reporting (reporting bias) 
• other sources of bias 
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Table 2.2: Criteria for assessing risk of bias in included studies
*
 
DOMAIN DESCRIPTION Risk of bias 
SEQUENCE 
GENERATION 
 
 
 
 
 
 
 
 
 
 
Comment:  
1. Was information 
provided? 
2. Were patients randomly 
allocated? 
3. Was randomization 
properly carried out? 
  
  
  
  
  
  
  
  
  
  
  
  
Was the allocation sequence adequately generated? 
UNCLEAR (unclear or unknown risk of bias) 
YES (low risk of bias): 
• Random number table 
• Coin tossing 
• Computer random number generator 
• Shuffling cards or envelopes 
• Throwing dice 
• Drawing of lots 
• Minimization 
NO (high risk of bias) 
• Odd or even date of birth 
• Date/day of admission 
• Hospital or clinic record number 
• Allocation by judgement of physician 
• Allocation by preference of participant 
• Allocation based on the result of a laboratory test 
• Allocation by availability of intervention 
ALLOCATION 
CONCEALMENT 
Describe allocation 
sequence method used 
  
  
  
  
  
  
  
  
  
Was the allocation sequence method used sufficient to 
conceal the intervention allocations? 
UNCLEAR: 
• Insufficient information 
YES (low risk of bias): 
• Central allocation - telephone, web-based, pharmacy 
• Controlled randomization 
• Sequentially numbered drug containers of identical 
appearance 
• Sequentially numbers opaque, sealed envelopes 
NO (high risk of bias): 
• Using an open random allocation schedule e.g. list 
of random numbers. 
• Assignment envelopes were used without appropriate 
safeguarding e.g.: unsealed, an opaque, non-
sequentially numbered 
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DOMAIN DESCRIPTION Risk of bias 
BLINDING OF 
PARTICIPANTS AND 
OUTCOME 
ASSESSORS 
 
 
 
 
 
 
 
 
 
 
Describe all measures 
  
  
  
  
  
  
  
  
  
  
  
  
Was knowledge of the allocated intervention adequately 
prevented during the study? 
UNCLEAR (unclear or unknown risk of bias) 
YES (low risk of bias): 
• No blinding - but the outcome and the outcome 
measurement are not likely to be influenced by lack 
of binding  
• Blinding of participants and key study personnel 
ensured and unlikely that the blinding could have 
been broken 
• Either participants or some key study personnel 
were not blinded, but outcome assessment was 
blinded and the non-blinding of others unlikely to 
introduce bias 
NO (high risk of bias): 
• No blinding/incomplete blinding and the outcome or 
outcome measurement is likely to be influenced by 
lack of blinding 
• Blinding attempted but likely could have been 
broken 
• Participants/key study personnel were not blinded 
and the non-blinding of others likely to introduce 
bias 
INCOMPLETE 
OUTCOME DATA 
Describe attrition 
Plus exclusions - reasons 
Plus any re-inclusion 
analysis performed 
  
  
  
  
  
  
  
  
Were incomplete outcome data adequately addressed? 
UNCLEAR: 
• Insufficient information 
• Study did not address this outcome 
YES (low risk of bias): 
• No missing outcome data - no dropouts  
• Reasons for missing outcome data unlikely to be 
related to true outcome 
• Missing outcome data balanced in numbers across 
intervention groups, with similar reasons for missing 
data across groups 
• Missing data have been imputed using appropriate 
methods 
NO (high risk of bias): 
• Reasons for missing outcome data likely to be related 
to true with either imbalance in numbers or reasons 
for missing data across intervention groups 
• Potentially inappropriate application of simple 
imputation 
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DOMAIN DESCRIPTION Risk of bias 
SELECTIVE OUTCOME 
REPORTING 
 
 
 
How was selective 
outcome reporting 
examined and findings? 
  
  
Are reports of the study free of suggestion of selective 
outcome reporting? 
UNCLEAR: 
• Insufficient information 
• Study did not address the outcome. 
YES (low risk of bias):  
• Protocol available, primary and secondary 
outcomes reported in the pre-specified way 
• Protocol NOT available but it is clear that the 
published reports include all expected outcomes, 
including those that were pre-specified 
NO (high risk of bias): 
• Not all pre-specified primary outcomes have been 
reported 
• One or more primary outcome is reported using 
measurements, analysis methods or subsets of 
data that were not pre-specified 
• One or more reported primary outcomes were 
not pre-specified (unless justification is provided) 
• One or more outcomes of interest are reported 
incompletely  
• Study fails to include results for a key outcome 
that would be expected to have been reported 
OTHER Other sources of bias not 
addressed by other 
domains 
Was the study free of other sources of bias? 
UNCLEAR 
YES 
NO 
*Table adapted from the 2008 Cochrane Handbook for Systematic Reviews of Interventions.
60 
Judgments were categorised to indicating a low, high, or unclear risk of bias respectively. The results were 
summarised using the ’Risk of bias summary’ and the ’Risk of bias graph’ in addition to the ’Risk of bias 
table’ for each included study. Where necessary, study authors were contacted for clarification and 
disagreements were resolved by consensus with other review authors. 
2.5.4 Measures of Treatment Effect   
Review Manager Version 5 (RevMan 2008) was used to conduct the analyses. Mean differences (MD) for 
continuous outcomes were calculated and the results were presented with 95% confidence intervals (CI). 
Medians and ranges for continuous data were reported in table format. There were no dichotomous 
outcomes in this review. 
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2.5.5 Unit of Analysis Issues   
There were no cross-over and cluster-randomized trials included in this review. For the one study with two 
active treatment arms for different doses of vitamin D versus one placebo arm, results were reported 
separately using pair-wise comparisons to avoid unit-of-analysis error as a result of double-counting 
participants. 
2.5.6 Dealing with Missing Data   
Where data were missing, authors of studies were contacted to obtain relevant missing information. 
Intention to treat (ITT) analyses were planned where there was no missing data. In the case of missing data, 
an available case analysis was planned. 
2.5.7 Assessment of Heterogeneity   
Although it had been planned to assess heterogeneity using both the Chi
2
 and I
2
 tests, this was not possible 
because there was no meta-analysis in this review. 
2.5.8 Assessment of Reporting Biases   
Funnel plots to assess evidence of publication bias were not constructed because less than ten trials were 
included. 
2.5.9 Data Synthesis   
Separate analyses were carried out for different medical conditions. Since there were few studies per 
condition and also because some outcomes were reported as different units of measurement, only effect 
sizes of individual studies could be calculated.  
2.5.10 Subgroup Analysis and Investigation of Heterogeneity   
No subgroup analysis or investigation of heterogeneity could be done because there was no meta-analysis 
in this review. If sufficient studies were available possible sub-group analyses would have been performed 
using different age groups, different genders, different forms of supplementation, different quality studies, 
different durations of intervention and different study sizes.  
Stellenbosch University  http://scholar.sun.ac.za
 36 
 
2.5.11 Sensitivity Analysis   
No sensitivity analyses to assess the influence of potential factors on the effect size could be done because 
there was no meta-analysis in this review. A sensitivity analysis would have been performed to explore the 
influence of the following factors on effect size: repeating the analysis taking account of trial quality; 
repeating the analysis excluding trials using the following filters- diagnostic criteria, language of publication, 
source of funding; repeating the anaylsis excluding various study designs. 
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CHAPTER 3: RESULTS 
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3.1 RESULTS OF THE SEARCH 
The results of the literature search yielded 338 studies (Fig.3.1). The database Science Direct identified 329 
publications but many were not directly related to the topic being investigated. A librarian performed the 
searches in the Scopus (5 publications with one duplicate), PUBMED (7 publications), Cochrane library (18 
publications with three duplicates) and Web of knowledge (69 publications with five duplications) (Table 
3.1). The local manufacturers of vitamin D supplementation, Georen pharmaceuticals and Arctic 
pharmaceuticals were contacted by personal interviews, but no additional records were indentified. After 
many of the irrelevant articles from Science Direct were excluded and duplicates excluded, 31 records were 
screened. Fourteen full text articles were assessed for eligibility, 10 were excluded. Four papers were 
included  but data did not allow meta-analyses. 
 
TABLE 3.1: Results of electronic searches 
DATABASE PERIOD 
SEARCHED 
SEARCH 
STRING 
NUMBER OF 
DUPLICATES 
TOTAL NUMBER 
RETRIEVED TO BE 
SCREENED 
SCIENCE DIRECT Inception to 
October 2010, 
repeated in May 
2012 
Topic=((metabolic syndrome OR insulin 
resistance OR abdominal obesity OR 
cardiometabolic OR visceral obesity)) AND 
Topic= ((vitamin D OR calcitriol OR 25 ohd 
OR 25 hydroxyvitamin D OR 25-ohd* OR 25-
hydroxyvitamin D OR 25 (oh)d)) AND 
Topic=((placebo OR no intervention OR 
without)) AND Topic=((waist circumference 
OR blood pressure OR hdl OR tg Or 
lipoprotein OR triglyceride OR glucose OR 
sugar OR insulin OR bmi OR 
proinflammatory OR prothrombotic OR 
fibrinogen OR plasminogen OR CRP OR C 
reactive protein OR IL OR interleukin)) 
- 329 
SCOPUS 1 5 
PUBMED - 7 
COCHRANE 
LIBRARY 
3 18 
WEB OF 
KNOWLEDGE 
5 69 
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Fig 3.1 Flow diagram demonstrating the searching and selection process  
# of irrelevant records removed. 
e.g. animal studies, textbook chapters. 
298 
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3.2 DESCRIPTION OF STUDIES 
3.2.1 Characteristics of Included Studies  
Four studies with a parallel-group design were included in the systematic review (Table 3.2). The 
first study by Parekh et al.Error! Bookmark not defined. was a randomized, double-blind, placebo-
controlled study in India, where twenty eight diabetic Asian Indian patients were randomly assigned 
to a vitamin D treated group (N=14) or a placebo group (N=14). The vitamin D treated group 
received 300,000IU D3 intramuscularly, once off. The patients were followed up for 4 weeks. The 
outcomes examined included: Serum 25-hydroxyvitamin D, haemoglobin AIc , HOMA-IR, serum 
fructosamine, serum insulin and oral glucose tolerance test was performed.  
The second study by Witham et al.33 in the United Kingdom, was a randomized, blinded, placebo-
controlled trial. Sixty one diabetic participants were randomized into three groups. One group 
received 100 000IU vitamin D3 (N=19) a second group 200 000IU vitamin D3 (N=20) and the third 
group was given a placebo (N=22). The participants were followed over a sixteen week period. The 
outcomes examined included serum 25 hydroxyvitamin D, blood pressure, insulin resistance, 
haemoglobin AIc, endothelial function and serum cholesterol. 
The third study by Zittermann et al.29 was a randomized blinded placebo-controlled trial in 
Germany. Two hundred over-weight participants were given either 3332 IU cholecalciferol daily 
(N=100) or placebo for one 1 year (N=100). The outcomes examined included: Serum 25- 
hydroxyvitamin D, fasting plasma glucose, blood pressure, serum cholesterol, triglycerides, serum 
LDL, tumour necrosis factor and body weight. 
The final study by Von Hurst et al.
11 
in New Zealand, was a randomized, placebo-controlled, double-
blind trial. This trial included insulin resistant South Asian Women (N=81). The vitamin D group 
(N=42) was given 4000IU D3 per day for six months. The outcomes examined included: Fasting 
plasma glucose, fasting serum insulin, HOMA 2%, CRP, serum, 25-hydroxyvitamin D. 
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TABLE 3.2: Characteristics of included studies  
STUDY DESIGN STUDY 1 Parekh et al.
31
 
(India)
 
STUDY 2 Witham et al.
33
 (U.K.) STUDY 3 Zittermann et 
al.
29
(Germany)
 
STUDY 4 Von Hurst et al.
11
 
(New Zealand)
 
Controls Intervention Controls Intervention 1 Intervention 2 Controls Intervention Controls Intervention 
TREATMENT 1 ml distilled 
water im 
serving as 
placebo 
Vitamin D3 
300000 iu im 
for 4 weeks 
Placebo: 
Miglyol oil 
Vitamin D3 100000 
iu once off 
Vitamin D3 
200000 iu once 
off 
5 drops 
vitamin d 
free oil 
(placebo) 
83.3 ug 
(3332iu) 
cholecalciferol 
daily for 12 
months 
4 oral 
placebo 
capsules 
Vitamin D3 
4000 iu per 
day for 6 
months 
NUMBER OF 
PATIENTS 
ALLOCATED TO 
EACH GROUP 
14 14 22 19 20 100 100 39 42 
NUMBER OF 
PATIENTS WHO 
COMPLETED 
TRIAL  
13 14 21 19 18 83 82 Not 
mentioned 
Not 
 mentioned 
REASONS GIVEN 
FOR NON-
COMPLIANCE OF 
TRIAL 
Yes Yes Yes Yes Yes Yes Yes Yes Yes 
DURATION OF 
FOLLOW-UP 
4 Weeks 4 Weeks 16 Weeks 16 Weeks 16 weeks 1 Year 1 Year 6 Months 6 Months 
GENDER Male + Female Male + Female Male + 
Female 
Male + Female Male + Female Male + 
Female 
Male + Female Female Female 
AGE RANGE 35-50 Years 35-50 Years 18 Years 
And Older 
18 Years And Older 18 Years and 
Older 
18-70 Years 18-70 Years 20+ Years 20+ Years 
RACE Asian Indian Asian  
Indian 
Not 
Specified 
Not  
Specified 
Not  
Specified  
Not 
Specified 
Not Specified South 
Asian 
South  
Asian 
Stellenbosch University  http://scholar.sun.ac.za
 42 
 
 
  
STUDY DESIGN STUDY 1 Parekh et al.
31
 
(India)
 
STUDY 2 Witham et al.
33
 (U.K.) STUDY 3 Zittermann et 
al.
29
(Germany)
 
STUDY 4 Von Hurst et al.
11
 
(New Zealand)
 
Controls Intervention Controls Intervention 1 Intervention 2 Controls Intervention Controls Intervention 
BODY MASS 
INDEX (kg/m
2
) 
(Mean) 
20-26  20-26  33.3 (7.1)  31.1 (6.7)/29.7 
(4.2)  
 >27 >27 27.4 27.5 
DIAGNOSIS OF 
DIABETES 
MELLITUS 
YES YES YES YES YES NO NO NO NO 
Diagnoses of 
impaired glucose 
tolerance 
YES YES  YES YES YES NO NO NO NO 
Vitamin D 
deficiency 
<25nmol/L 
(Mean) 
16.74(6.69) 14.91(6.76)  - - - - - 19 21  
Vitamin D 
insufficiency 40-
80 nmol/L (Mean) 
 - -  45(17) 41(14) 48(21)  30.3(20.1)  30(17.5) - - 
Component of MS 
present in 
subjects 
Elevated 
blood glucose 
Elevated 
blood glucose 
Elevated 
blood 
glucose 
Elevated blood 
glucose 
Elevated blood 
glucose 
Elevated 
waist 
circumferen
ce 
Elevated waist 
circumference 
Impaired 
glucose 
tolerance 
Impaired 
glucose 
tolerance 
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Serum 25(OH)D: Serum 25 – Hydroxyvitamin D, HbAIc: Haemoglobin AIc, HOMA-IR: Homeostasis model assessment for insulin sensitivity, OGTT: Oral Glucose Tolerance Test, BP: 
Blood Pressure, TNF: Tumour Necrosis Factor, FPG: Fasting Plasma Glucose,    CRP: C Reactive Protein, HOMA 2%: Insulin Resistance
STUDY DESIGN 
STUDY 1 Parekh et al.
31
 
(India)
 STUDY 2 Witham et al.
33
 (U.K.) STUDY 3 Zittermann et 
al.
29
(Germany)
 
STUDY 4 Von Hurst et al.
11
 
(New Zealand)
 
Controls Intervention Controls Intervention 1 Intervention 2 Controls Intervention Controls Intervention 
Outcomes 
measured 
Serum 25(OH)D 
HbAIc 
HOMA-IR 
Serum Fructosamine 
Serum Insulin 
OGTT 
Serum 25 (OH)D 
BP 
Insulin Resistance 
HbAIc 
Endothelial Function 
Serum Cholesterol 
Serum 25 (OH)D 
FPG 
BP 
Serum Cholesterol 
Triglycerides 
Serum LDL 
TNF 
Body Weight 
Serum 25 (OH)D 
FPG 
Serum Insulin 
HOMA 2% 
CRP 
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The total number of subjects measured for each outcome is shown in Table 3.3.  
There were different outcomes measured in each study. Each of the components of the 
metabolic syndrome were examined across the included studies. However, none of the studies 
assessed all of the components.  
Table 3.3: Total number of subjects examined for each outcome 
25-hydroxyvitamin D 373 
Haemoglobin AIc 173 
HOMA IR 89 
HOMA 2% 84 
Serum fructosamine 28 
Serum insulin 112 
Plasma glucose 112 
Blood pressure 261 
Endothelial function 61 
Serum cholesterol 261 
Triglycerides 200 
Serum LDL 200 
Tumour necrosis factor 200 
Body weight 200 
CRP 84 
 
3.2.2 Characteristics of Excluded Studies (Relevant records only) 
Reasons for the exclusion of trials from the systematic review are described in Table 3.4. Ten 
trials were excluded because they were not conducted as randomized controlled trials, one 
paper was only the protocol (the whole article was subsequently published and included in the 
review (excluding the protocol) and one paper was an Iranian publication that could not be 
accessed. Five papers had problems with the diagnosis of the components of the metabolic 
syndrome and in four of these neither vitamin D deficiency or insufficiency was present. A 
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further 10 full-text articles were excluded. Characteristics of excluded randomised controlled 
studies are described in Table 3.5. 
The trial by De Boer et al.
55
 examined the effect of calcium and vitamin D supplementation on 
the incidence of diabetes in post menopausal women. It was a randomized controlled trial, 
participants were given 1000mg calcium and 400IU of vitamin D3 daily or placebo. This trial 
included 33,951 participants. The participants were followed up for a seven year period. Results 
indicated that supplementation did not reduce the risk of developing diabetes. The study was 
excluded from the systematic review because the patients did not have at least one component 
of the metabolic syndrome at diagnosis. In addition vitamin D measurements were not 
available for all patients; they were only available for a select group of patients. 
The trial by Pittas et al.56 compared the effects of combined calcium and vitamin D 
supplementation versus placebo on blood glucose and markers of inflammation in non-diabetic 
adults. The study was designed as a randomized double blind, controlled trial, where 
participants received either 500mg calcium and 700IU vitamin D3 or placebo daily for 3 years. 
The findings of this trial were that supplementation may attenuate increases in glycaemia and 
insulin resistance in patients with impaired fasting glucose. This study was excluded from the 
systematic review because only some of the patients were diagnosed with one of the 
components of the metabolic syndrome and not all the patients were vitamin D deficient or 
insufficient. 
The trial by Nagpal et al.
34
 looked at the effects of vitamin D3 supplementation on insulin 
sensitivity in healthy, centrally obese men. This was a double-blind randomized controlled trial, 
100 patients were given 3 doses of vitamin D3 (120 000IU each) fortnightly or placebo. The 
group was followed up for six weeks. The conclusion of the trial was that vitamin D3 
supplementation improved postprandial insulin sensitivity. The study was excluded from the 
systematic review because although the criterium of waist circumference was used as the 
component of the metabolic syndrome, not all the patients would always have a significantly 
raised waist circumference. 
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The study by Jorde et al.22 examined the effect of vitamin D on cardiovascular risk factors. The 
trial was a double blind placebo-controlled intervention trial. A total of 438 patients were 
randomized to receive either 40 000IU vitamin D per week, 20 000IU vitamin D per week or 
placebo, all patients were given 500mg calcium daily. The follow up period was one year. The 
outcomes did not find a positive effect of vitamin D supplementation on glucose tolerance, 
blood pressure or serum lipids. The study was excluded as it met none of the inclusion criteria. 
Avenell et al.53 conducted a randomized controlled trial. The primary outcome was to look at 
the effects of vitamin D3 on the development of diabetes. The 5292 patients were randomized 
to take 800IU vitamin D3 daily, 1000mg calcium daily, both or placebo. This trial did not find 
vitamin D3 had a protective effect against the development of type 2 diabetes. The study was 
excluded as it did not meet any of  the inclusion criteria.  
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Table 3.4: Excluded studies with reasons (Relevant records only) 
Title Reason For Exclusion 
Science Direct: 
Vitamin D metabolism and cardiovascular risk factors in 
postmenopausal women
46 
Not a RCT 
 
Serum 25-hydroxyvitamin D is independently associated with high-
density lipoprotein cholesterol and the metabolic syndrome in men 
and women
47 
Not a RCT 
 
Poor vitamin D status may contribute to high risk for insulin 
resistance, obesity and cardiovascular disease in Asian Indians48 
Not a RCT 
 
Vitamin D deficiency is the cause of common obesity
266 Not a RCT 
 
Cardiovascular risk in menopausal women and prevalent related 
coma-bid conditions: facing - the post-women’s health initiative 
era49 
Not a RCT 
 
Influence of obesity on vitamin D-binding protein and 25 
hydroxyvitamin D levels in African American and white women 57 
Not a RCT 
 
Vitamin D and type 2 diabetes: Is there a link?51  Not a RCT 
 
Interaction of 25-hydroxyvitamin D levels with metabolic 
characteristics in polycystic ovary syndrome52 
Not a RCT 
 
Pubmed: 
Vitamin D supplementation and type 2 diabetics: a sub study of a 
randomised placebo-controlled trial in older people (RECORD trial, 
ISRCTN 51647438)53  
 
No vitamin D deficiency/ 
insufficiency, no metabolic 
syndrome 
Study protocol - Metabolic syndrome, vitamin D and bone status in 
South Asian women living in Auckland, New Zealand: A randomized, 
placebo-controlled, double-blind vitamin D intervention.54  
Only a protocol  
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Title Reason For Exclusion 
The Cochrane Library: 
A double-blind, randomized, placebo controlled 
trial of the short-term effect of vitamin D3 
supplementation an insulin sensitivity in 
apparently healthy, middle-aged centrally obese 
men
34 
Sent to third reviewer 
Exclude- not all the patients would always 
have a sufficiently raised waist 
circumference to meet inclusion criteria 
Calcium and vitamin D supplementation and the 
risk of incident diabetes in the women’s health 
initiative55 
1. Excluded- Patients did not have 
components of metabolic syndrome at 
diagnosis 
2. Vitamin D concentrations were only 
available for a select group of patients 
The effects of calcium and vitamin D 
supplementation on blood glucose and markers 
of inflammation in non-diabetic adults56 
Sent to third reviewer 
Consensus on paper sent to third reviewer: 
Exclude 
Not all the patients will be vitamin D 
insufficient which is one of the inclusion 
criteria. 
ISI Web of Knowledge: 
Vitamin D intake is associated with insulin 
sensitivity in African American, but not 
European American women57 
Exclude - not RCT 
Hypovitaminosis D in Chinese type 2 diabetes: 
Lack of impact on clinical metabolic status and 
biomarkers of cellular inflammation58 
Exclude - not RCT 
Assessment of vitamin D supplementation effect 
on insulin resistance among type 2 diabetic 
patients 
IRANIAN PUBLICATION - not accessible 
No improvement in cardiovascular risk factors in 
overweight and obese subjects after 
supplementation with vitamin D3 for one year22 
Exclude - none of the metabolic components i.e.: 
blood pressure, plasma glucose, serum LDL, serum 
HDL met the diagnostic criteria for the metabolic 
syndrome There was no Vitamin D deficiency or 
insufficiency 
*RCT: Randomised Controlled Trial 
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Table 3.5: Characteristics of excluded randomised controlled studies  
 Study Intervention Duration 
of follow 
up 
Study subjects Age 
range 
(years) 
BMI 
(kg/m2) 
Diagnosis 
of diabetes 
mellitus 
Diagnosis 
of impaired 
glucose 
tolerance 
Diagnosis with 
one of the 
components of 
the metabolic 
syndrome 
Vitamin D 
deficiency 
<25 nmol/L 
Vitamin d 
insufficiency 
40-80- nmol/L 
 
De Boere et al.51 
1000mg 
calcium 
400iu vitamin D 
daily 
7yrs Postmenopausal 
women 
(N= 2,291) 
50-79 - Not all 
subjects 
Not all 
subjects 
Patients did not 
have components 
of the metabolic 
syndrome at 
diagnosis 
Vitamin d 
concentrations were 
only available for a 
select group of patients 
Vitamin d 
concentrations 
were only available 
for a select group 
of patients 
 
Pittas et al.52 
500mg calcium 
700iu vitamin D  
Daily 
3yrs Caucasian adults 
(N=314 ) 
>=65  27.8 +- .6 No Yes Yes (some of the 
patients) 
Not all patients Not all patients 
  
 Nagpal et al.31 
120 000iu 
vitamin D 3 
doses 
fortnightly 
 6 weeks  Male 
(N=100 ) 
 >=35  No No Not all 
subjects 
 Not all the 
patients would 
always  
have a 
significantly raised 
waist circumference 
Yes Yes 
Jorde et al.19 Vitamin D 40 
000/20 000 per 
week calcium 
500mg daily 
1yr Male and female 
(N=438 ) 
21-70  28-47  No No No No No 
Avenell et al.49 800iu vitamin D 
daily and or 
1000 mg 
calcium 
24-62 
months 
Male and female 
(N= 5292) 
>=70  - No No No No No 
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3.3 RISK OF BIAS IN INCLUDED STUDIES  
The risk of bias in individual included studies are summarised in Tables 3.6 – 3.9.  
Selection Bias: 
Parekh
31
, Zittermann
29
 and Von Hurst’s
11
 studies did not provide sufficient information 
regarding allocation concealment. There was no selection bias in Witham’s
33
 study. 
 
Performance Bias: 
All the trials were adequately blinded and free of performance bias. 
 
Detection Bias: 
All the trials were free of detection bias. 
 
Attrition Bias: 
The studies of Parekh
31
 and Zittermann
29
 did not have attrition bias, but bias was present in 
Witham
33
 and Von Hurst’s
11
 papers. 
 
Reporting Bias: 
All the studies were free of reporting bias. 
 
Other Bias: 
No other sources of bias were present. 
The protocols were not searched for. 
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Table 3.6: Risk of bias table 1 (Parekh et al.)31 
PILOT STUDY TO EVALUATE THE EFFECT OF SHORT-TERM IMPROVEMENT IN VITAMIN D 
STATUS ON GLUCOSE TOLERANCE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS 
ENTRY JUDGEMENT DESCRIPTION 
Adequate sequence generation? Unclear Insufficient information  
Quote: “randomization was performed 
with use of simple randomization” 
Allocation concealment? Unclear Not reported 
Blinding? Yes “Double blind, placebo-controlled pilot 
study”.  
Quote: “Placebo or cholecalciferol 
injections were administered by a person 
unaware of the randomization 
assignment” 
Probably done 
Incomplete outcome data addressed? Yes 1 missing from control group  versus 
none from the treatment group 
Quote: “withdrew from the study after 
baseline investigations” 
No reasons provided. 
Free of selective reporting? Yes Protocol not available but the published 
reports included all data 
Free of other bias? Yes  
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Table 3.7: Risk of bias table 2 (Witham et al.)33 
THE EFFECT OF DIFFERENT DOSES OF VITAMIN D3 ON MARKERS OF VASCULAR HEALTH IN 
PATIENTS WITH TYPE 2 DIABETES: A RCT 
ENTRY JUDGEMENT DESCRIPTION 
Adequate sequence 
generation? 
Yes Quote: “Tayside Pharmaceuticals prepared a computer-
generated randomization code stored in sealed 
envelopes until the end of the study” 
Probably done 
Allocation 
concealment? 
Yes Quote: “Each participant was given the next numbered 
medication bottle in sequence to preserve allocation 
concealment”. 
Probably done 
Blinding? Yes Quote: “The participants and the research team 
remained blinded to treatment allocation until after the 
main analyses were completed”. 
Probably done 
Incomplete outcome 
data addressed? 
No 8 week visit: 3 missing from intervention group 2;  
16 week visit: 1 missing from control group; 2 missing 
from intervention group 2. 
Reasons differ across groups 
Free of selective 
reporting? 
Yes Protocol not available but the published reports include 
all data. 
Free of other bias? Yes  
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Table 3.8: Risk of bias table 3 (Zittermann et al.)29 
VITAMIN D SUPPLEMENTATION ENHANCES THE BENEFICIAL EFFECTS OF WEIGHT LOSS ON CVD 
RISK MARKERS 
ENTRY JUDGEMENT DESCRIPTION 
Adequate sequence 
generation? 
Yes Quote: “all participants were randomly assigned in a double-
blind manner from computer generated random number 
list.” 
Probably done 
Allocation 
concealment? 
Unclear Insufficient information 
Blinding? Yes Quote: “At study entry all participants were randomly 
assigned in a double-blind manner” 
Probably done 
Incomplete outcome 
data addressed? 
Yes Quote: “the number of dropouts did not differ between study 
groups (P > 0,05)” 
Intervention group: Started 100 
Lost to follow up: 18 
Non-compliant : 15 
Disease : 1 
Pregnant : 2 
Final no. of drop-outs: 36 
Placebo group 100 : Started 100 
Lost to follow up: 17 
Non-compliance: 15 
Disease : 1 
Pregnancy: : 1 
Final no. of drop-outs: 34 
Free of selective 
reporting? 
Yes Protocol not available but the published reports include all 
data 
Free of other bias? Yes  
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Table 3.9: Risk of bias table 4 (Von Hurst et al.)
11 
VITAMIN D SUPPLEMENTATION REDUCES INSULIN RESISTANCE IN SOUTH ASIAN WOMEN 
LIVING IN NEW ZEALAND WHO ARE INSULIN-RESISTANT PLUS VITAMIN D DEFICIENT - A 
RANDOMIZED, PLACEBO-CONTROLLED TRIAL 
ENTRY JUDGEMENT DESCRIPTION 
Adequate sequence 
generation? 
Yes Quote: “Randomisation of the Vitamin D/placebo capsules and 
allocation to the members of each pair were performed by 
Blackmores Ltd using a query Advisor, version 6.0 (statistical 
solutions) “ 
Probably done 
Allocation 
concealment? 
Unclear Quote: “randomisation + allocation were fully concealed from 
the researchers until after statistical analysis of data” 
Insufficient info for patients 
Blinding? Yes Quote: “randomized, placebo-controlled, double-blind trial” 
Incomplete 
outcome data 
addressed? 
No There was an imbalance in numbers between groups. 
Free of selective 
reporting? 
Yes Protocol not available but the published reports include all data 
Free of other bias? Yes  
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Figure 3.2: Risk of bias graph 
 
 
 
Figure 3.3: Risk of bias summary for individual trials 
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3.4 EFFECTS OF INTERVENTIONS   
3.4.1 The Influence of Vitamin D Administration on Components of the Metabolic 
Syndrome  
3.4.1.1  Comparison 1: The effect of vitamin D versus placebo in patients with type 2 diabetes 
mellitus who were also vitamin D insufficient.  
Two studies (Parekh 2010
 31 and Witham 201033) assessed the effect of vitamin D versus placebo 
in patients with Type 2 diabetes mellitus. The results from Witham 2010
 33  are shown in Table 
3.10 and the results from Parekh 2010
 31 are shown in Table 3.11.  
Table 3.10: The effect of vitamin D versus placebo in patients with type 2 diabetes mellitus –
Witham 2010 study33 
 
Characteristic                          Treatment group 100,000IU vitamin D 
versus Placebo 
 
200,000IU vitamin D 
versus Placebo 
 
100,000IU 
vitamin D 
(n=19) 
200,000IU 
vitamin D 
(n=20) 
Placebo       
(n=22) 
Unit of information Mean (SD) Mean (SD)  Mean (SD) Mean Difference (95% CI) Mean Difference (95% CI) 
Systolic BP (mmHg) 
Baseline 
8 Weeks 
16 Weeks 
 
 
149.6 (24) 
141.4 (16.6) 
144.6 (20.4) 
 
 
145.1 (25) 
136.8 (12.9) 
139.5 (15.4) 
 
 
143.9 (24.4) 
146.4 (19.5) 
143.4 (16.4) 
 
 
 
-5.00 (-16.05 to 6.05) 
 1.20 (-10.35 to 12.75) 
 
 
 
-9.00 (-19.76 to 0.56) 
-3.90 (-13.89 to 6.09) 
Diastolic BP (mmHg) 
Baseline 
8 Weeks 
16 Weeks 
 
 
81.7 (12.4) 
77.1 (11.7) 
79.6 (11.9) 
 
 
80.7 (14.3) 
74.4 (9.8) 
77.6 (11.7) 
 
 
80.3 (9.7) 
78.9 (9.2) 
78.4 (10.3) 
 
 
 
-1.80 (-8.32 to 4.72) 
 1.20 (-5.73 to 8.13) 
 
 
 
-4.50 (-10.54 to 1.54) 
-0.80 (-7.77 to 6.17) 
Cholesterol (total) 
(mmol/L) 
Baseline 
8 Weeks 
16 Weeks 
 
 
4.09 (1.14) 
3.90 (1.00) 
3.88 (0.92) 
 
 
4.07 (0.97) 
3.69 (0.71) 
3.94 (0.77) 
 
 
3.66 (0.71) 
3.77 (0.75) 
3.83 (0.89) 
 
 
 
0.13 (-0.42 to 0.68) 
0.05 (-0.51 to 0.61) 
 
 
 
-0.08 (-0.52 to 0.36) 
0.11 (-0.39 to 0.61) 
HbA1c (%) 
Baseline 
8 Weeks 
16 Weeks 
 
7.0 (1.6) 
7.1 (2.0) 
6.9 (1.5) 
 
6.9 (0.8) 
7.0 (0.7) 
6.7 (0.9) 
 
7.8 (1.3) 
7.6 (1.3) 
7.5 (1.4) 
 
 
-0.50 (-1.55 to 0.55) 
-0.60 (-1.49 to 0.29) 
 
 
-0.60 (-1.22 to 0.02) 
-0.80 (-1.51 to -0.09) 
HOMA IR 
Baseline 
8 Weeks 
16 Weeks 
 
11.7 (12.7) 
13.5 (12.8) 
15.9 (14.3) 
 
12.0 (14.5) 
11.9 (10.4) 
10.5 (7.2) 
 
13.0 (9.7) 
25.3 (33.6) 
17.2 (19.3) 
 
 
-11.80 (-26.97 to 3.37) 
-1.30 (-11.76 to 9.16) 
 
 
-13.40 (-28.29 to 1.49) 
-6.70 (-15.60 to 2.20) 
Serum 25(OH)D 
(nmol/L) 
Baseline 
8 Weeks 
16 Weeks 
 
 
41 (14) 
63 (20) 
59 (18) 
 
 
48 (21) 
79 (31) 
76 (30) 
 
 
45 (17) 
54 (20) 
53 (20) 
 
 
 
9.00 (-3.28 to 21.28) 
6.00 (-5.78 to 17.78) 
 
 
 
25.00 (8.06 to 41.94) 
23.00 (6.71 to 39.29) 
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FMD (%) 
Baseline 
8 Weeks 
16 Weeks 
 
5.1 (3.0) 
4.3 (2.3) 
5.2 (2.1) 
 
6.4 (3.2) 
4.9 (3.2) 
6.5 (2.6) 
 
5.4 (2.7) 
5.2 (3.1) 
5.1 (1.8) 
 
 
-0.90 (-2.56 to 0.76) 
0.10 (-1.11 to 1.31) 
 
 
-0.30 (-2.21 to 1.61) 
1.40 (0.03 to 2.77) 
SD=Standard Deviation, CI=Confidence Interval, BP=Blood Pressure, HbA1c =Glycated Haemoglobin, HOMA IR=Homeostasis 
Model Assessment for Insulin Sensitivity, 25(OH)D=25 hydroxyvitamin D, FMD=Flow-Mediated Dilation 
 
 
Table 3.11: The effect of vitamin D versus placebo in patients with type 2 diabetes mellitus –
Parekh 201031 
 
Characteristic                          Treatment group Vitamin D versus Placebo 
 Vitamin D       
(n=14) 
Placebo  
(n=14) 
Unit of information Mean (SD) Mean (SD) Mean Difference (95% CI) 
Fasting plasma glucose –OGTT at 120min (mg/dl) 
Baseline 
Final (4 Weeks) 
Final – Baseline 
 
225.36 (69.78) 
228.36 (52.18) 
3.0 (63.03) 
 
229.71 (42.81) 
215.54 (44.94) 
-14.23 (60.07) 
 
 
12.82 (-23.84 to 49.48) 
17.23 (-29.21 to 63.27) 
Serum Insulin –OGTT at 120min (uIU/ml) 
Baseline 
Final (4 Weeks) 
Final – Baseline 
 
78.98 (43.42) 
63.25 (31.31) 
-15.72 (37.88) 
 
64.91 (17.83) 
79.75 (40.63) 
13.87 (44.61) 
 
 
-16.50 (-44.01 to 11.01) 
-29.59 (-60.92 to 1.74) 
Serum Fructosamine (umol/L) 
Baseline 
Final (4 Weeks) 
Final – Baseline 
 
306.21 (29.94) 
316.36 (30.13) 
10.14 (35.32) 
 
322.14 (26.07) 
313.15 (24.99) 
-8.54 (37.00) 
 
 
3.21 (-17.61 to 24.03) 
18.68 (-8.65 to 46.01) 
HbA1c (%) 
Baseline 
Final (4 Weeks) 
Final – Baseline 
 
7.58 (0.57) 
7.67 (0.61) 
0.09 (0.69) 
 
7.83 (0.63) 
7.63 (0.60) 
-0.18 (0.87) 
 
 
0.04 (-0.42 to 0.50) 
0.27 (-0.33 to 0.87) 
HOMA IR 
Baseline 
Final (4 Weeks) 
Final – Baseline 
 
13.69 (7.48) 
13.01 (6.16) 
-0.71 (5.31) 
 
13.78 (5.28) 
14.51 (6.92) 
0.81 (7.17) 
 
 
-1.50 (-6.46 to 3.46) 
-1.52 (-6.31 to 3.27) 
Serum 25(OH)D (nmol/L) 
Baseline 
Final (4 Weeks) 
Final – Baseline 
 
14.91 (6.76) 
41.59 (12.21) 
26.69 (14.33) 
 
16.74 (6.69) 
17.98 (4.36) 
0.73 (4.22) 
 
 
23.61 (16.79 to 30.43) 
25.96 (18.11 to 33.81) 
 
SD=Standard Deviation, CI=Confidence Interval, OGTT=Oral Glucose Tolerance Test, HbA1c =Glycated Haemoglobin, HOMA 
IR=Homeostasis Model Assessment for Insulin Sensitivity, 25(OH)D=25 hydroxyvitamin D 
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Primary outcomes   
• BMI 
This outcome was not evaluated by either of the two studies. 
• Blood pressure 
The Witham 2010 study
 33 measured systolic and diastolic BP (mmHg) at baseline, 8 weeks, and 
at 16 weeks (Table 3.10). There were two active treatment groups with differing dosages, that 
is, 100,000 IU and 200,000IU once off. At 8 weeks, there were no significant differences 
observed in systolic BP both in the 100,000IU group (MD -5.00, 95%CI: -16.05 to 6.05, 41 
participants) and the 200,000IU group (MD -9.00, 95%CI: -19.76 to 0.56, 39 participants) 
compared to the placebo. Also at 8 weeks, there were no significant differences observed for 
diastolic blood pressure both in the 100,000IU group (MD -1.80, 95%CI: -8.32 to 4.72, 41 
participants) and 200, 000IU group (MD -4.50, 95%CI: -10.54 to 1.54, 39 participants) compared 
to the placebo. At 16 weeks, the systolic BP levels were not significantly different from placebo 
for both the 100, 000IU group (MD 1.20, 95%CI: -10.35 to 12.75, 40 participants) and the 200, 
000IU group (MD -3.90, 95%CI: -13.89 to 6.09, 39 participants). Similarly at 16 weeks, the values 
for diastolic BP were not significantly different from placebo for both the 100, 000IU group (MD 
1.20, 95%CI: -5.73 to 8.13, 40 participants) and the 200, 000IU group (MD -0.80, 95%CI: -7.77 to 
6.17, 39 participants). 
The treatment effects for change in BP from baseline to either 8 weeks or 16 weeks could not 
be calculated because the standard deviations of change were not reported. 
The Parekh 2010 study31 did not report on BP. 
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• Lipid profiles LDL, HDL, triglyceride levels  
Total cholesterol 
 The Witham 2010 study
 33 measured total cholesterol (mmol/L) and the results in Table 3.10 
shows no significant differences in cholesterol levels between vitamin D and placebo at both 8 
weeks (100,000IU vitamin D: MD 0.13, 95%CI: -0.42 to 0.68, 41 participants; 200,000IU vitamin 
D: MD -0.08, 95%CI: -0.52 to 0.36, 39 participants) and 16 weeks (100,000IU vitamin D: MD 
0.05, 95%CI: -0.51 to 0.61, 41 participants; 200,000IU vitamin D: MD 0.11, 95%CI: -0.39 to 0.61, 
39 participants). The treatment effects for change in cholesterol from baseline to either 8 
weeks or 16 weeks could not be calculated because the standard deviations of change were not 
reported. 
The Parekh 2010 study
 31 did not report on total cholesterol. 
• Blood glucose, insulin profiles, HOMA IR 
Blood glucose 
The Witham 2010 study
 33 did not report on blood glucose. 
The Parekh 2010 study
 31 reported the plasma glucose (mg/dL) and serum insulin (μIM/ml) 
levels during an oral glucose tolerance test (OGTT) at 0, 30, 60, 90, and 120 minutes (Table 
3.11). Treatment effects were calculated using values at 120 minutes. There were no significant 
differences in the final values at 4 weeks for both glucose (MD 12.82, 95%CI: -23.84 to 49.48, 27 
participants) and insulin (MD -16.50, 95%CI: -44.01 to 11.01, 27 participants) between the 
vitamin D and placebo groups. 
The results also showed that no significant differences were observed in the change (from 
baseline to 4 weeks) in both glucose (MD 17.23, 95%CI: -29.21 to 63.67, 27 participants) and 
insulin levels (MD -29.59, 95%CI: -60.92 to 1.74, 27 participants) between the vitamin D and 
placebo group.  
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HbA1c 
The Witham 2010 study33 reported the glycolated haemoglobin (HbA1c%) levels at baseline, 8 
weeks, and at 16 weeks (Table 3.10). At 8 weeks, there were no significant differences between 
the placebo and both 100,000IU vitamin D group (MD -0.50, 95%CI: -1.55 to 0.55, 41 
participants) and the 200,000IU vitamin D group (MD -0.60, 95%CI: -1.22 to 0.02, 39 
participants). However at 16 weeks, although there were no significant differences between the 
placebo and the 100,000IU vitamin D group (MD -0.60, 95%CI: -1.49 to 0.29, 40 participants), 
there were significantly fewer HbA1c levels in the 200,000IU vitamin D group compared to 
placebo (MD -0.80, 95%CI: -1.51 to -0.09, 39 participants). The treatment effects for change in 
HbA1c levels from baseline to either 8 weeks or 16 weeks could not be calculated because the 
standard deviations of change were not reported. 
The Parekh 2010 study31 also reported HbA1c (%) levels at baseline, 4 weeks, and for the 
change from baseline to 4 weeks (Table 3.11). There were no significant differences in the 
HbA1c final values at 4 weeks (MD 0.04, 95%CI: -0.42 to 0.50, 27 participants). The results also 
showed no significant difference in the change in HbA1c levels from baseline to 4 weeks 
between the vitamin D group compared to the placebo group (MD 0.27, 95%CI: -0.33 to 0.87, 
27 participants).  
The results for HbA1c levels from the two studies could not be pooled in a meta-analysis 
because they reported results at different time periods. 
Serum fructosamine 
The Witham 2010 study
 33 did not report on serum fructosamine.  
The Parekh 2010 study31 reported on serum fructosamine (umol/l) levels at baseline, 4 weeks, 
and for the change from baseline to 4 weeks (Table 3.11). There were no significant differences 
in the serum fructosamine final values at 4 weeks (MD 3.21, 95%CI: -17.61 to 24.03, 27 
participants). The results also showed no significant difference in the change in serum 
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fructosamine levels from baseline to 4 weeks between the vitamin D group and the placebo 
group (MD 18.68, 95%CI: -8.65 to 46.01, 27 participants).  
HOMA IR 
The Witham 2010 study
 33
 reported the HOMA IR levels at baseline, 8 weeks, and at 16 weeks 
(Table 3.10). At 8 weeks, there were no significant differences between the placebo and both 
100,000IU vitamin D group (MD -11.80, 95%CI: -26.97 to 3.37, 41 participants) and the 
200,000IU vitamin D group (MD -13.40, 95%CI: -28.29 to 1.49, 39 participants). Similarly at 16 
weeks, no significant differences were evident between the placebo and both 100,000IU 
vitamin D group (MD -1.30, 95%CI: -11.76 to 9.16, 40 participants) and the 200,000IU vitamin D 
group (MD -6.70, 95%CI: -15.60 to 2.20, 39 participants). The treatment effects for change in 
HOMA IR from baseline to either 8 weeks or 16 weeks could not be calculated because the 
standard deviations of change were not reported. 
The Parekh 2010 study31 reported HOMA IR levels at baseline, 4 weeks, and for the change from 
baseline to 4 weeks (Table 3.11). There were no significant differences in the HOMA IR final 
values at 4 weeks (MD -1.50, 95%CI: -6.46 to 3.46, 27 participants). The results also showed no 
significant difference in the change in HOMA IR levels from baseline to 4 weeks between the 
vitamin D group and the placebo groups (MD -1.52, 95%CI: -6.31 to 3.27, 27 participants).  
The results for HOMA IR levels from the two studies could not be pooled in a meta-analysis 
because they reported results at different time periods. 
• Serum 25(OH)D 
The Witham 2010 study33 reported the serum 25 hydroxyvitamin D (25(OH)D) levels (ng/mL) at 
baseline, 8 weeks, and at 16 weeks (Table 3.10). The 200,000IU Vitamin D group had 
significantly higher levels of 25(OH)D than the placebo group at both 8 weeks (MD 25.00, 
95%CI: 8.06 to 41.94, 39 participants) and 16 weeks (MD 23.00, 95%CI: 6.71 to 39.29, 39 
participants) although there were no significant differences observed between the 100,000IU 
vitamin D and placebo groups at both 8 weeks (MD 9.00, 95%CI: -3.28 to 21.28, 41 participants) 
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and 16 weeks (MD 6.00, 95%CI: -5.78 to 17.78, 40 participants). The treatment effects for 
change in serum 25(OH)D levels from baseline to either 8 weeks or 16 weeks could not be 
calculated because the standard deviations of change were not reported. 
The Parekh 2010 study31 also reported on serum 25(OH)D levels at baseline, 4 weeks, and for 
the change from baseline to 4 weeks (Table 3.11). The final serum 25(OH)D levels at 4 weeks 
were significantly higher in the vitamin D group than the placebo group (MD 23.61, 95%CI: 
16.79 to 30.43, 27 participants). The results also showed a significantly greater increase in 
serum 25(OH)D levels in the vitamin D group than the placebo group from baseline to 4 weeks 
(MD 25.96, 95%CI: 18.11 to 33.81, 27 participants). 
The results for serum 25(OH)D levels from the two studies could not be pooled in a meta-
analysis because they reported results at different time periods. 
Secondary outcomes   
• Proinflammatory states fibrinogen, plasminogen, C-reactive protein (CRP) 
interleukins. 
Flow-Mediated Dilation (FMD) 
The Witham 2010 study
 33 reported the FMD (%) levels at baseline, 8 weeks, and at 16 weeks 
(Table 3.10). At 8 weeks, there were no significant differences between the placebo and both 
100,000IU vitamin D group (MD -0.90, 95%CI: -2.56 to 0.76, 41 participants) and the 200,000IU 
vitamin D group (MD -0.30, 95%CI: -2.21 to 1.61, 39 participants). However at 16 weeks, 
although there were no significant differences between the placebo and the 100,000IU vitamin 
D group (MD 0.10, 95%CI: -1.11 to 1.31, 40 participants), there were significantly higher FMD 
levels in the 200,000IU vitamin D group compared to placebo (MD 1.40, 95%CI: 0.03 to 2.77, 39 
participants). The treatment effects for change in FMD levels from baseline to either 8 weeks or 
16 weeks could not be calculated because the standard deviations of change were not 
reported. 
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• Prothrombotic state 
This outcome was not evaluated by the two studies assessing comparison 1. 
3.4.1.2  Comparison 2: The effect of vitamin D versus placebo in 
patients with vitamin D deficiency and insulin resistance 
One study (von Hurst 2010)
 11
 assessed this comparison for patients having both vitamin D 
deficiency and insulin resistance (Table 3.12). 
Primary outcomes   
• BMI 
The study reported values for BMI at baseline only. It is reported that there were no significant 
changes in BMI during the study in either the vitamin D or placebo groups. 
• Blood pressure 
Systolic and diastolic blood pressures were only reported at baseline and at 16 weeks in the one 
study assessing this comparison. Both systolic and diastolic blood pressures were slightly 
increased at 16 weeks, compared to 8 weeks. 
• Lipid profiles LDL, HDL, triglyceride levels 
The values for LDL-, HDL-cholesterols, and TAG were only reported at baseline. It is reported 
that changes in HDL-cholesterol and TAG from baseline were not significant either within or 
between the vitamin D and placebo groups. 
• Blood glucose, insulin profiles, HOMA IR 
Changes in fasting serum glucose (FSG) between baseline and 6 months (end of study) did not 
significantly differ both within and between the vitamin D and placebo groups (Table 3.12). 
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However, significant improvements were observed in fasting serum insulin (FSI) with vitamin-D 
supplementation compared with placebo (p=0.02 as reported by study authors, Table 3.12). 
It is reported that a significant difference was observed in the change in HOMA1-IR between 
the vitamin D and placebo study groups (p=0.03 as reported by study authors, Table 3.12). The 
authors reported a median (IQR) decrease of -0.25 (0.24, -0.81) in the vitamin D group and an 
increase of 0.36 (1.16, -0.41) in the placebo group. 
• Serum 25(OH) vitamin D 
A significant increase in serum 25(OH) vitamin D concentrations was observed both within and 
between the vitamin D-supplemented and placebo groups from baseline to 6 months of study 
(p<0.001 as reported by study authors, Table 3.12). 
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Table 3.12: The effect of vitamin D versus placebo in patients with insulin resistance –von Hurst 2010 study
11
 
Characteristic                                                Treatment group Vitamin D versus 
Placebo 
 
                  Vitamin D  (n=42)                  Placebo (n=39) 
 
Unit of information Median (IQR) P-value 
(Differen
ce within 
group) 
Median (IQR) P-value 
(Difference 
within group) 
P-value (Difference 
between groups) 
FSG (mmol/L) 
Baseline 
Final (6 months) 
Final - Baseline 
 
4.7 (4.5 to 5.1) 
4.8 (4.6 to 5.2) 
0.1 (0.4 to -0.1) 
 
0.154 
 
4.9 (4.5 to 5.2) 
5.0 (4.7 to 5.4) 
0.1 (0.4 to -0.2) 
 
0.07 
 
 
 
0.82 
FSI (mU/L) 
Baseline 
Final (6 months) 
Final - Baseline 
 
13.2 (10.1 to 16.8) 
11.2 (7.9 to 11.9) 
-1.3 (-3.6 to 1.0) 
 
0.02 
 
11.9 (9.9 to 15.4) 
13.1 (10.2 to 17.3) 
1.1 (-2.5 to 4.2) 
 
0.27 
 
 
 
0.02 
HOMA1- IR 
Baseline 
Final (6 months) 
Final - Baseline 
 
2.70 (2.13 to 3.61) 
NR 
-0.25 (0.24 to -0.81) 
 
NR 
 
2.53 (2.11 to 3.47) 
NR 
0.36 (1.16 to -0.41) 
 
NR 
 
 
 
0.03 
25(OH)D (nmol/L) 
Baseline 
Final (6 months) 
Final - Baseline 
 
21 (11 to 40) 
80 (67 to 94) 
49 (21 to 66) 
 
<0.001 
 
19 (13 to 29) 
29 (23 to 36) 
  8 (-1 to 16) 
 
< 0.001 
 
 
 
< 0.001 
hs-CRP (mg/L) 
Baseline 
Final (6 months) 
Final - Baseline 
 
2.50 (1.0 to 4.5) 
2.15 (1.25 to 3.4) 
0.00 (-1.05 to 0.4) 
 
0.19 
 
2.4 (1.0 to 4.6) 
2.9 (1.5 to 4.6) 
0.2 (-0.1 to 0.7) 
 
0.38 
 
 
 
0.05 
IQR=Interquartile Range (25
th 
to 75
th
 percentile), NR=Not Reported, FSG=Fasting Serum Glucose, FSI=Fasting Serum Insulin, 
HOMA1-IR=Homeostasis Model Assessment for Insulin Sensitivity (Model 1), 25(OH)D=25 hydroxyvitamin D, hs-CRP=high 
sensitivity C-reactive Protein. 
 
 
 
Secondary outcomes   
• Pro-inflammatory states fibrinogen, plasminogen, C-reactive protein (CRP) 
interleukins 
The study reported no significant differences in changes in high sensitivity C-reactive protein 
(CRP) both within and between the vitamin D and placebo groups during the study (Table 3.12). 
• Prothrombotic state 
This outcome was not evaluated by the two studies assessing comparison 2. 
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3.4.1.3   Comparison 3: The effect of vitamin D versus placebo on 
weight loss in overweight vitamin D deficient patients 
One study (Zittermann 2009) 29 assessed this comparison for overweight patients (Table 3.13). 
Primary outcomes   
• BMI 
The  Zittermann 2009 study29 reported on BMI (kg/m
2
) at baseline, 12 months, and for the 
change from baseline to 12 months (Table 3.13). There were no significant differences in the 
BMI final values at 12 months between the vitamin D and placebo groups (MD 0.90, 95%CI: -
0.46 to 2.26, 165 participants). The results also showed no significant difference in the change 
in BMI from baseline to 12 months between the vitamin D and the placebo groups (MD 0.20, 
95%CI: -0.40 to 0.80, 165 participants).  
• Blood pressure 
Systolic BP 
The  Zittermann 2009 study29 reported on systolic BP (mmHg) at baseline, 12 months, and for 
the change from baseline to 12 months (Table 3.13). There were no significant differences in 
the systolic BP final values at 12 months between the vitamin D and placebo groups (MD -1.0, 
95%CI: -5.59 to 3.59, 165 participants). The results also showed no significant difference in the 
change in systolic BP from baseline to 12 months between the vitamin D and the placebo 
groups (MD -1.0, 95%CI: -5.88 to 3.88, 165 participants). 
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Table 3.13: The effect of vitamin D versus placebo in overweight patients–Zittermann 2009 study
29
 
 
Characteristic Treatment group Vitamin D versus 
Placebo 
 
Vitamin D  (n=82) Placebo (n=83) 
 
Unit of information Mean (SD) Mean (SD) Mean Difference (95% 
CI) 
BMI (kg/m
2
) 
Baseline 
Final (12 months) 
Final – Baseline 
 
33.7 (4.1) 
31.8 (4.3) 
-2.0 (2.0) 
 
33.0 (4.3) 
30.9 (4.6) 
-2.2 (1.9) 
 
 
0.90 (-0.46 to 2.26) 
0.20 (-0.40 to 0.80) 
Systolic BP (mmHg) 
Baseline 
Final (12 months) 
Final – Baseline 
 
128 (15) 
124 (14) 
-4 (16) 
 
128 (14) 
125 (16) 
-3 (16) 
 
 
-1.0 (-5.59 to 3.59) 
-1.0 (-5.88 to 3.88) 
Diastolic BP (mmHg) 
Baseline 
Final (12 months) 
Final – Baseline 
 
86 (8) 
83 (8) 
-3 (9) 
 
86 (9) 
83 (9) 
-3 (10) 
 
 
0.0 (-2.60 to 2.60) 
0.0 (-2.90 to 2.90) 
LDL cholesterol 
(mmol/l) 
Baseline 
Final (12 months) 
Final – Baseline 
 
 
3.52 (0.93) 
3.70 (1.04) 
0.19 (1.03) 
 
 
3.65 (0.78) 
3.57 (0.91) 
-0.09 (0.64) 
 
 
 
0.13 (-0.17 to 0.43) 
0.28 (0.02 to 0.54) 
HDL cholesterol 
(mmol/L) 
Baseline 
Final (12 months) 
Final – Baseline 
 
 
1.46 (0.38) 
1.44 (0.36) 
-0.02 (0.22) 
 
 
1.51 (0.37) 
1.46 (0.40) 
-0.04 (0.20) 
 
 
 
-0.02 (-0.14 to 0.10) 
0.02 (-0.04 to 0.08) 
Triglycerides (mmol/L) 
Baseline 
Final (12 months) 
Final – Baseline 
 
1.43 (0.68) 
1.23 (0.50) 
-0.19 (0.54) 
 
1.31 (0.57) 
1.35 (0.74) 
0.03 (0.50) 
 
 
-0.12 (-0.31 to 0.07) 
-0.22 (-0.38 to -0.06) 
Glucose (mmol/L) 
Baseline 
Final (12 months) 
Final – Baseline 
 
5.67 (0.78) 
5.44 (0.61) 
-0.21 (0.51) 
 
5.67 (1.17) 
5.39 (0.72) 
-0.27 (0.82) 
 
 
0.05 (-0.15 to 0.25) 
0.06 (-0.15 to 0.27) 
HbA1c (%) 
Baseline 
Final (12 months) 
Final – Baseline 
 
5.62 (0.40) 
5.37 (0.30) 
-0.25 (0.23) 
 
5.66 (0.57) 
5.42 (0.44) 
-0.25 (0.23) 
 
 
-0.05 9-0.16 t 0.06) 
0.00 (-0.07 to 0.07) 
25(OH)D (nmol/L) 
Baseline 
Final (12 months) 
Final – Baseline  
 
30.0 (17.5) 
85.5 (57.5) 
55.5 (55.8) 
 
30.3 (20.1) 
42.0 (35.0) 
11.8 (36.3) 
 
 
43.50 (28.95 to 58.05) 
43.70 (29.32 to 58.08) 
Interleukin-6 (pg/ml) 
Baseline 
Final (12 months) 
Final – Baseline 
 
8.9 (15.2) 
5.4 (4.5) 
-3.5 (14.0) 
 
7.8 (12.3) 
6.0 (5.4) 
-1.9 (10.9) 
 
 
-0.60 (-2.12 to 0.92) 
-1.60 (-5.43 to 2.23) 
Tumour necrosis factor-
alpha (pg/ml) 
Baseline 
Final (12 months) 
Final – Baseline 
 
 
7.84 (3.15) 
7.04 (2.25) 
-0.80 (2.5) 
 
 
8.12 (3.43) 
7.90 (2.80) 
-0.26 (2.9) 
 
 
 
-0.86 (-1.63 to -0.09) 
-0.54 (-1.37 to 0.29) 
SD=Standard Deviation, CI=Confidence Interval, BMI=Body Mass Index, BP=Blood Pressure, LDL-Low Density Lipoprotein, 
HDL=High Density Lipoprotein, HbA1c =Glycated Haemoglobin, HOMA IR=Homeostasis Model Assessment for Insulin Sensitivity, 
25(OH)D=25 hydroxyvitamin D. 
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Diastolic BP 
The  Zittermann 2009 study29 reported on diastolic BP (mmHg) at baseline, 12 months, and for 
the change from baseline to 12 months (Table 3.13). There were no significant differences in 
the diastolic BP final values at 12 months between the vitamin D and placebo groups (MD 0.0, 
95%CI: -2.60 to 2.60, 165 participants). The results also showed no significant difference in the 
change in diastolic BP from baseline to 12 months between the vitamin D and the placebo 
groups (MD 0.0, 95%CI: -2.90 to 2.90, 165 participants). 
• Lipid profiles LDL, HDL, triglyceride levels 
LDL-cholesterol 
The  Zittermann 2009 study29 reported on LDL-cholesterol (mmol/l) at baseline, 12 months, and 
for the change from baseline to 12 months (Table 3.13). There were no significant differences in 
the final values at 12 months between the vitamin D and placebo groups (MD 0.13, 95%CI: -
0.17 to 0.43, 165 participants).  However, vitamin D supplementation significantly increased LDL 
cholesterol levels from baseline to 12 months compared to the placebo group (MD 0.28, 95%CI: 
0.02 to 0.54, 165 participants). 
HDL-cholesterol 
The  Zittermann 2009 study
29
 reported on HDL-cholesterol levels (mmol/l) at baseline, 12 
months, and for the change from baseline to 12 months (Table 3.13). There were no significant 
differences in the final values at 12 months between the vitamin D and placebo groups (MD -
0.02, 95%CI: -0.14 to 0.10, 165 participants). The results also showed no significant difference in 
the change from baseline to 12 months between the vitamin D and the placebo groups (MD 
0.02, 95%CI: -0.04 to 0.08, 165 participants). 
 
 
Stellenbosch University  http://scholar.sun.ac.za
 69 
 
Triglycerides 
The  Zittermann 2009 study29 reported on triglyceride levels (mmol/l) at baseline, 12 months, 
and for the change from baseline to 12 months (Table 3.13). There were no significant 
differences in the triglyceride final values at 12 months between the vitamin D and placebo 
groups (MD -0.12, 95%CI: -0.31 to 0.07, 165 participants). The results also showed that vitamin 
D supplementation significantly decreased triglyceride levels from baseline to 12 months 
compared to the placebo groups (MD -0.22, 95%CI: -0.38 to -0.06, 165 participants). 
• Blood glucose, insulin profiles, HOMA IR 
Glucose 
The  Zittermann 2009 study29 reported on glucose (mmol/l) at baseline, 12 months, and for the 
change from baseline to 12 months (Table 3.13). There were no significant differences in the 
glucose final values at 12 months between the vitamin D and placebo groups (MD 0.05, 95%CI: -
0.15 to 0.25, 165 participants). The results also showed no significant difference in the change 
from baseline to 12 months between the vitamin D and the placebo groups (MD 0.06, 95%CI: -
0.15 to 0.27, 165 participants). 
HbA1c 
The  Zittermann 2009 study29 reported on HbA1c (%) at baseline, 12 months, and for the change 
from baseline to 12 months (Table 3.13). There were no significant differences in the values at 
12 months between the vitamin D and placebo groups (MD -0.05, 95%CI: -0.16 to 0.06, 165 
participants). The results also showed no significant difference in the change from baseline to 
12 months between the vitamin D and the placebo groups (MD 0.00, 95%CI: -0.07 to 0.07, 165 
participants). 
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• Serum 25(OH)D 
The  Zittermann 2009 study29 reported on 25(OH)D at baseline, 12 months, and for the change 
from baseline to 12 months (Table 3.13). The final values at 12 months were significantly higher 
in the vitamin D group compared to the placebo group (MD 43.50, 95%CI: 28.95 to 58.05, 165 
participants). The results also showed that vitamin D supplementation significantly increased 
the 25(OH)D levels from baseline to 12 months compared to the placebo group (MD 43.70, 
95%CI: 29.32 to 58.08, 165 participants). 
Secondary outcomes   
• Proinflammatory states fibrinogen, plasminogen, C-reactive protein (CRP) 
interleukins 
Tumour-Necrosis Factor (TNF)  
The  Zittermann 2009 study29 reported on TNF (pg/ml) at baseline, 12 months, and for the 
change from baseline to 12 months (Table 3.13). The final values at 12 months were 
significantly lower in the vitamin D group compared to the placebo group (MD -0.86, 95%CI: -
1.63 to -0.09, 165 participants). The results showed no significant difference in the change from 
baseline to 12 months between the vitamin D and the placebo groups (MD -0.54, 95%CI: -1.37 
to 0.29, 165 participants). 
Interleukin-6 
The  Zittermann 2009 study29 reported on interleukin-6 levels (pg/ml) at baseline, 12 months, 
and for the change from baseline to 12 months (Table 3.13). There were no significant 
differences in the final values at 12 months between the vitamin D and placebo groups (MD -
0.60, 95%CI: -2.12 to 0.92, 165 participants). The results also showed no significant difference in 
the change from baseline to 12 months between the vitamin D and the placebo groups (MD -
1.60, 95%CI: -5.43 to 2.23, 165 participants). 
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• Prothrombotic state 
This outcome was not evaluated by the study assessing comparison 3. 
3.4.2  Adverse Effects Associated with Vitamin D Administration 
In the trial by Zittermann et al.
29
 it was found that LDL-cholesterol was significantly increased in 
the vitamin D treated group. No other adverse events were reported in any of the trials. 
3.4.3  Dose-response Effect of Vitamin D Supplementation 
The Witham33 study investigated two different doses of vitamin D 100000IU and 200000IU. The 
200000IU group did show a slightly more significant improvement in flow mediated dilatation 
(Table  3.10) and a decrease in B-type natriutretic peptide levels. 
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CHAPTER 4: DISCUSSION 
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4.1 SUMMARY OF MAIN RESULTS  
 
The primary objective of this systematic review was to examine the effect of vitamin D 
supplementation on the components of the metabolic syndrome. Four trials were included in 
this review.  
Several outcomes were examined. These included blood pressure, where both Zittermann
29
 
and Witham’s
33
 studies looked at blood pressure as an outcome and showed no significant 
differences in both systolic and diastolic blood pressure in either trials. 
A second outcome investigated was lipid profiles, including total cholesterol, LDL, HDL and 
triglyceride levels. The Witham
33
 study measured total cholesterol. The results showed no 
significant differences in cholesterol levels between the vitamin D and placebo groups. The 
Zittermann
29
 study showed no significant difference in the final value of LDL between groups, 
however vitamin D supplementation significantly increased LDL cholesterol levels from baseline 
to 12 months in the vitamin D treated group. 
Zittermann
29
 also examined HDL and triglycerides. These showed no significant differences 
between the two groups.  
Plasma glucose and serum insulin were measured in Parekh’s trial.
31
 There was no significant 
difference between the vitamin D and placebo group for both blood glucose and insulin at 4 
weeks. Zittermann’s study
29
 also reported on blood glucose and found no significant changes 
between the groups.  
Three studies, Witham’s
33
, Parekh’s
31
 and Zittermann’s
29
 investigated HbA1c.  
Witham’s trial
33
 showed no difference between the groups at 8 weeks, But at 16 weeks the 
HbA1c levels were lower in the 200 000 iu vitamin D treated group compared to placebo. 
 Parekh
31
 and Zittermann’s
29
 trials found no significant differences between the groups for 
HbA1c. 
Neither Witham
33
 nor Parekh
31
 found any significant difference in Homa IR levels between 
intervention and control group. Von Hurst’s study
11
 found no significant changed in fasting 
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serum glucose between the groups, however significant improvements were observed in 
fasting serum insulin in the vitamin D versus the placebo group. A significant difference was 
also seen in Homa IR between vitamin D and placebo group.  
BMI was examined in Zittermann’s
29
 study and no significant differences were found between 
the two groups. 
The studies all showed an increase in 25(OH)D levels in the vitamin D groups compared to the 
placebo. 
The studies all looked at various outcomes or end points. With the results presented in this 
systematic review, one could not be confident to make a positive recommendation on the use 
of vitamin D in any of the components of the metabolic syndrome. 
4.2. QUALITY AND APPLICABILITY OF THE EVIDENCE   
The random allocation was adequate in three studies, insufficient information concealment was 
provided in Parekh’s study31. The allocation concealment was adequate in Zittermann29 and 
Witham’s studies33, but unclear in Parekh31 and Von Hurst’s
11
 studies.  
The reasons for withdrawals were given in all the studies except Parekh’s31, and the number of 
dropouts was clear in all studies except Von Hurst’s.
11
 
The ideal systematic review would have been made up of trials that used all of the diagnostic 
criteria of the metabolic syndrome as their end-point, however no such trials were available.  
The four studies included in this systematic review differed in their outcomes and no single 
study focused on all the diagnostic criteria of the metabolic syndrome. The trials were 
heterogeneous in terms of measured outcomes looking at different components of the 
metabolic syndrome. 
The included trials used varying doses of vitamin D, ranging from 3332IU daily, 4000IU daily, 
100 000IU, 200 000IU to 300 000IU once off. The duration of follow up was also widespread, 
spanning 4 weeks to 12 months.  The chances of a positive effect are more likely to be seen 
when using higher doses of vitamin D supplementation for a longer period of time.  
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The studies included were all of small sample size. Sample size is an important factor in 
determining the accuracy and repeatability of the results. If the sample size is too small there is 
a greater chance that the power of the study is too low to identify real and significant 
differences. 
Attrition bias was addressed in half the studies. Attrition bias should have been taken into 
account in all the studies. The exclusion of the subjects from the analysis could lead to an 
overestimate of the effectiveness of the intervention. 
4.3 POTENTIAL BIASES IN THE REVIEW PROCESS  
Only randomized controlled trials were included in this systematic review. Only studies for 
which the investigator could obtain full text articles were included. It is possible that some 
published trials may have been missed in this review since the researcher did not have access 
to all possible databases. The literature search was performed in October 2010 and was 
repeated in 2012. A potential for bias may have occurred due to the exclusion of one non-
English study – an Iranian publication. The review had several limitations including 
comprehensiveness of the literature search and hand searches of article references were not 
done. The search was however comprehensive in terms of the variety of electronic data bases 
searched. Another limitation is that additional outcomes were addressed by the investigator 
that were not initially specified in the protocol.  
 
4.4 AGREEMENTS AND DISAGREEMENTS WITH OTHER STUDIES OR 
REVIEWS  
In recent editorial in the British Medical Journal
59
 the author called for some perspective 
regarding vitamin D supplementation. The high profile news coverage and the promotion of the 
results of observational studies as if they proved causality have resulted in unsubstantiated 
claims of benefits of vitamin D. 
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Several factors in the studies looking at vitamin D and its impact on diseases can make 
interpretation complex. The first of these factors is the definition of normality regarding vitamin 
D status. Studies have reported the serum 25 hydroxyvitamin D concentration at which PTH 
reaches a plateau to be between 25nmol/L and 75nmol/L, making it difficult to deduce a 
functional definition of vitamin D deficiency.
59
 
Most evidence linking low vitamin D status to non-bone outcomes has been derived from 
observation. All studies are observational and can be limited by several factors. These include: 
reverse causality (disease may cause reduced exposure to sun), confounders (low physical 
activity may cause low vitamin D, obesity and increased risk of diabetics), classification bias 
(vitamin D status defined in terms of diet, not blood concentrations which correlate poorly with 
nutritional intake) and differences in assay methods.59 
The safety of supplementing large segments of the population with vitamin D over a prolonged 
period of time is unknown. The editorial in the British medical journal
59
 called for large, well 
designed randomized controlled trials with long-term follow up to prove the benefit, lack of 
benefit or even harm of vitamin D supplementation.  
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5.1 IMPLICATIONS FOR PRACTICE   
Vitamin D is promoted to have beneficial effects for treating and preventing different 
components of the metabolic syndrome which affects large segments of populations 
worldwide. In our systematic review we, however, found that currently available evidence is 
not sufficient to support the use of vitamin D supplementation for this purpose. The available 
evidence also provides no assurance regarding the safety of long-term vitamin D 
supplementation.  
The metabolic syndrome and its various components present a daily challenge for the clinical 
practitioner. It would be of enormous clinical benefit if it could be documented by evidence 
based practice that supplementation with vitamin D could in some way have a positive effect 
on any of the components of the metabolic syndrome. This would provide a relatively cheap 
option when used in adequate dosages and would provide benefits outweighing any harm. 
The current evidence available as summarised in this review is limited as it is not definitive and 
gives no clear guidelines.   
The primary papers examined in this review were relatively free of bias. There was no 
publication, detection or reporting bias in any of the papers. Half of the papers were free of 
attrition bias and one was free of selection bias.  
5.2 IMPLICATIONS FOR RESEARCH   
This review highlights the need for further large, well-designed randomized controlled trials in 
this area. Ideally, it would be favourable to assess vitamin D supplementation in patients with 
as many components of the metabolic syndrome as possible. It has been noted in several of the 
studies that the stage of the disease i.e. insulin resistance versus type II diabetes, and the 
severity of hypertension had an impact on how significant the effect vitamin D supplementation 
was.
5
 Future trials need to include all age groups, including the  elderly as they are vulnerable 
to vitamin D deficiency. Both male and female patients must be included, as well as various 
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ethnic groups as darker skinned individuals have lower vitamin D levels5
 
and effects of 
supplementation and relationship to disease on all ethnic groups has to be examined. Obesity 
influences vitamin D status, so various ranges of BMI’s need to be accounted for. Confounders 
such as seasonal variation also need to be taken into account. 
It will be important to standardize vitamin D dosages used, and to include information on the 
use of alternative supplementation and dietary information. It is very important that an 
adequate dosage of vitamin D is supplemented, that baseline vitamin D status must be 
assessed, and to ensure that deficient patients reach sufficient levels for an effect to be seen.  
The trials should also be of sufficient duration to allow for positive or negative outcomes to be 
reached.  
With a sufficient number of high quality RCTs a systematic review and meta-analysis can then 
be performed to provide clinicians with evidence based data on which to base their clinical 
practice. It will improve our understanding of the impact of vitamin D supplementation on 
clinical conditions that practitioners treat on a daily basis. 
5.3 DECLARATION OF INTEREST  
No declaration of interest. 
There were no conflicts of interest in this review nor were any stated in the included studies. 
 
5.4 DEVIATIONS FROM PROTOCOL 
In the original protocol trials with all the components of the metabolic syndrome were to be 
included, however no such studies were found with our literature search. The protocol was 
then amended to include trials with at least one component of the metabolic syndrome.  
 
5.5 SOURCES OF SUPPORT 
None. 
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ADDENDUM A  
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SELECTION CRITERIA 
 Table 1 
    Include Exclude 
STUDY DESIGN (STUDY TYPE)       
CONTROLS       
DURATION OF FOLLOW UP MONTHS:         DAYS:       
PATIENT CHARACTERISTICS       
HUMAN SUBJECTS       
RACE GROUPS: 
CAUCASIAN                           NUMBERS                               % 
AFRICAN                                NUMBERS                              % 
INDIAN                                   NUMBERS                               % 
  
      
AGE OF PARTICIPANTS      MEAN                                    SD       
COMPONENTS OF THE METABOLIC SYNDROME: 
FOR STUDIES TO BE INCLUDED AT LEAST ONE COMPONENT OF THE 
METABOLIC SYNDROME MUST BE PRESENT 
Elevated waist circumference                                                            
Elevated triglycerides ≥ 1.7 mmol/L  or drug treatment for increased 
triglycerides is an alternate indicator 
  
Reduced HDL-C               (≤ 1.0mmol/L in males females≤ 1.3mmol/L 
or drug treatment)                  is an alternate indicator 
  
Elevated blood pressure (Systolic ≥ 130 diastolic ≥ 85mmHg and/or 
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antihypertensive drug treatment in a patient with a history of 
hypertension)     is an alternate indicator 
  
Elevated fasting glucose (≥  5.6mmol/L or drug treatment of elevated 
glucose is an alternative indicator) 
*SEE TABLE AT END 
  
VITAMIN D CRITERIA       
  
VITAMIN D DEFICIENCY <25NMOL /L 
      
VITAMIN D INSUFFICIENCY 40-80 NMOL/L       
EXCLUSION CRITERIA       
PREGNANT OR LACTATING WOMEN       
CO-MORBID DISEASE STATES: 
a.    KIDNEY DISEASE/ FAILURE 
b.    LIVER DISEASE/ FAILURE 
      
TYPES OF INTERVENTION       
VITAMIN D2 OR D3 ADMINISTRATION       
DOSAGE       
DURATION       
ROUTE OF ADMINISTRATION       
MONOTHERAPY OR COMBINATION THERAPY       
COMPARISON GROUP: 
PLACEBO 
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NO INTERVENTION 
CONCOMITANT THERAPY       
DIETARY RECOMMENDATIONS       
PHYSICAL ACTIVITY RECOMMENDATIONS       
COMPLIANCE       
 
Table 2  
      
TOTAL NUMBER OF SUBJECTS ENROLLED I N TRIAL:          
                   INTERVENTION GROUP    CONTROL GROUP 
TOTAL NUMBER OF SUBJECTS WHO COMPLETED TRIAL:    INTERVENTION 
GROUP     CONTROL GROUP       FINAL GROUP SIZE  
  
REASONS GIVEN FOR NON COMPLIANCE TRIAL YES NO 
PERCEIVED SIDE EFFECTS PREGNANCY                   MOVING                         
LOST TO FOLLOW UP       WITHDREW FROM STUDY    OTHER 
    
      
ALL DROPOUTS ACCOUNTED FOR     
ADVERSE EFFECTS:         HYPERCALCAEMIA      HYPERVITAMINOSIS D    
HYPERPHOSPHATAEMIA   OTHER 
    
INTENTION TO TREAT 
PER PROTOCOL                          ACTUAL CASE ANALYSIS 
    
STATISTICS     
1.    ARE THE GROUPS COMPARABLE AND IF NECESSARY ADJUSTED 
FOR BASELINE DIFFERENCES? 
2.    HAVE RECOGNIZED STATISTICS TESTS BEEN USED? 
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3.    WERE PAIRED TESTS USED IN PAIRED DATA? 
4.    WAS A 2 TAILED TEST PERFORMED WHENEVER THE EFFECT OF AN 
INTERVENTION COULD BE A NEGATIVE ONE? 
5.    WERE OUTLIERS ANALYSED APPROPRIATELY WITH CORRECT 
STATISTICAL ADJUSTMENTS? 
6.    HAS CORRELATION BEEN DISTINGUISHED FROM REGRESSION HAS THE 
CORRELATION CO-EFFICIENT VALUE
 
BEEN CALCULATED AND INTERPRETED 
CORRECTLY?   
ETHICAL APPROVAL 
SOURCE OF FUNDING 
    
  
PRIMARY OUTCOMES 
OUTCOME DATA FOR INTERVENTION AND CONTROL GROUPS 
   Baseline End 
   Mean SD CI P-
Value 
    Mean SD CI 
BMI (KG/M
2
) Intervention                
 Control                
WC (cm) Intervention                
 Control                
BP (mmHg) Intervention                
  Control                   
LDLmmol/L Intervention                
  Control                   
HDL  Intervention                
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 Control                
Cholesterol Intervention                
  Control                   
HOMA 2% 
TG 
Intervention                
  Control                   
FSG 
mmol/L 
BG 
Intervention                
  Control                   
FSI mmol/L 
Insulin 
Intervention                
                      
Serum 25 
HydroxyVit. 
D. nmol/L 
Intervention                
  Control                   
HOMA 2-IR Intervention                
  Control                   
HOMA –IR Intervention                   
  Control                   
  
HOMA 2 – IR-insulin Resistance 
FSI - Fasting serum insulin 
FSG – Fasting serum glucose 
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SECONDARY OUTCOMES 
   Mean SD CI P-
Value 
Mean SD CI P-
Value 
Plasminogen 
mg/dl 
Interve
ntion 
         
 Control          
C-
Reactive 
Protein 
mg/L 
Interve
ntion 
         
 Control          
Interleuki
ns 
Interve
ntion 
         
   
 
Table 1: Diagnostic Criteria of Metabolic Syndrome 
IDF NCEP WHO AACE 
Diagnosed if 
glycaemia is abnormal 
and 2 further criteria 
are present 
Diagnosed if 3 
out of 5 
criteria are 
present 
Diagnosed if 
glycaemia is abnormal 
and further 2 criteria 
are present 
Indicates risk 
factors 
Fasting glycaemia 
100-125 mg/dl or 
DM2 
Glycaemia 
110-125 mg/dl 
Glucose intolerance 
DM2 or insulin-
resistance due to 
HOMA-IR 
Fasting 
glycaemia 110-
125 
Mg/dl ≥ 140 mg/dl 
2 hours after oral 
GTT 
WC ≥ 94cm MWC WC > 102 cm 
MWC > 88 cm 
BMI > 30 and HWR > BMI ≥ 25 and 
WC > 102 cm 
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≥ 80cm W W 0.9M and > 0.85 W M and WC > 88 
cm W 
Tg ≥ 150 mg/dl or 
HDL < 40M and < 
50W 
TG ≥ 150mg/dl 
or HDL < 40 M 
and < 50W 
TG ≥ 150mg/dl or HDL 
< 35 M and < 39 W 
TG ≥ 150mg/dl 
or HDL < 40 M 
and < 50W 
On treatment for 
SAH or BP ≥ 
130x85 mmHg 
BP ≥ 130x85 
mmHg 
On treatment for SAH 
or BP ≥ 160x90 mmHg 
Microalbuminuria≥ 20 
mcg/min 
BP ≥ 130/85 
mmHg 
AACE = American College of Endocrinology/American Association of Clinical Endocrinologists; 
BMI = body mass index; BP = arterial blood pressure;  DM2 = diabetes mellitus type 2;  GTT = 
oral glucose tolerance test; HOMA = homeostasis model assessment;  HWR = hip: waist ratio;  
IDF = International Diabetes Federation;  M = men’  NCEP = US National Cholesterol Education 
Program;  SAH = systemic arterial hypertension; Tg = triglycerides;  W = women; WC = waist 
circumference; WHO = World Health Organisation. 
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